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Inflammatory Proteins, Genetic Variation, and Environmental Influences on
Health Care Associated Infection Development in Sepsis
Abstract
The purpose of this study was to determine the impact of baseline systemic inflammation
(pro‑inflammatory cytokine, anti‑inflammatory cytokine, and their ratio), genetic variability, and
environment on the development of health care associated infections (HAI) among sepsis patients during
their ICU stay (up to 28 days).
Methods: A prospective observation study was conducted at the Veterans Affairs Medical Center in the
Medical Intensive Care Unit over an 18 month period. A total of 78 patients were enrolled within 72 hours
of presenting to the ICU with sepsis. Patient were excluded if they were receiving immunosuppressants
(chemotherapy or greater than one mg/kg of prednisone or equivalent dose), immunosuppressed (AIDS,
cancer), or had liver failure (Child Pugh category C or higher). Baseline plasma and buccal swabs were
collected. Patients were followed prospectively through their ICU stay (or for a maximum of 28 days) for
the development of HAI as defined by CDC guidelines. Primary variables included baseline IL‑6 and IL‑10
levels, IL‑6 SNP rs1800795, IL‑10 SNP rs1800896, APACHE II, invasive devices, and development of HAI.
Results: A total of 17 HAI were identified with 64% caused by Candida. There were no significant
differences in levels of pro‑inflammatory cytokine, anti‑inflammatory cytokine, or their ratio among
subjects who did and did not develop at least one HAI during their ICU stay. There were also no significant
differences in rs1800795 or rs1800896 genotypes for those who did and did not develop HAI; however,
racial differences were detected in genotypes among white and black patients with sepsis who did and
did not develop HAI. There was a significant difference in rs1800795 genotype among black patients with
sepsis who did not develop HAI compared to whites patients with sepsis who did not develop HAI (p =
0.006). Specifically, black patients had a lower CG (17.4% vs. 42.1%) and higher GG (82.6% vs. 42.1%)
than white patients. There were no racial differences when comparing white and black sepsis patients
who developed HAI (p = 1.0). In a series of Cox regression analyses investigating timing to first HAI
among those who did and did not develop HAI during ICU stay, the final model included only APACHE II,
cumulative invasive device score, and IL‑6 rs1800795.
Conclusion
Conclusion: This study provides evidence of a genetic risk for development of HAI. Despite best
evidenced based practices some patients will develop HAI. Strict aseptic technique is essential to
preventing infection. In addition to eliminating invasive devices as quickly as possible, patients with a high
severity of illness may need to be isolated to lower their risk. Early administration of antibiotics not only
provides prompt treatment for the initial infection but also lowers risk for subsequent infections.
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ABSTRACT
The purpose of this study was to determine the impact of baseline systemic
inflammation (pro-inflammatory cytokine, anti-inflammatory cytokine, and their ratio),
genetic variability, and environment on the development of health care associated
infections (HAI) among sepsis patients during their ICU stay (up to 28 days).
Methods: A prospective observation study was conducted at the Veterans Affairs
Medical Center in the Medical Intensive Care Unit over an 18 month period. A total of 78
patients were enrolled within 72 hours of presenting to the ICU with sepsis. Patient were
excluded if they were receiving immunosuppressants (chemotherapy or greater than one
mg/kg of prednisone or equivalent dose), immunosuppressed (AIDS, cancer), or had liver
failure (Child Pugh category C or higher). Baseline plasma and buccal swabs were
collected. Patients were followed prospectively through their ICU stay (or for a
maximum of 28 days) for the development of HAI as defined by CDC guidelines.
Primary variables included baseline IL-6 and IL-10 levels, IL-6 SNP rs1800795, IL-10
SNP rs1800896, APACHE II, invasive devices, and development of HAI.
Results: A total of 17 HAI were identified with 64% caused by Candida. There
were no significant differences in levels of pro-inflammatory cytokine, anti-inflammatory
cytokine, or their ratio among subjects who did and did not develop at least one HAI
during their ICU stay. There were also no significant differences in rs1800795 or
rs1800896 genotypes for those who did and did not develop HAI; however, racial
differences were detected in genotypes among white and black patients with sepsis who
did and did not develop HAI. There was a significant difference in rs1800795 genotype
among black patients with sepsis who did not develop HAI compared to whites patients
with sepsis who did not develop HAI (p = 0.006). Specifically, black patients had a lower
CG (17.4% vs. 42.1%) and higher GG (82.6% vs. 42.1%) than white patients. There were
no racial differences when comparing white and black sepsis patients who developed
HAI (p = 1.0). In a series of Cox regression analyses investigating timing to first HAI
among those who did and did not develop HAI during ICU stay, the final model included
only APACHE II, cumulative invasive device score, and IL-6 rs1800795.
Conclusion: This study provides evidence of a genetic risk for development of
HAI. Despite best evidenced based practices some patients will develop HAI. Strict
aseptic technique is essential to preventing infection. In addition to eliminating invasive
devices as quickly as possible, patients with a high severity of illness may need to be
isolated to lower their risk. Early administration of antibiotics not only provides prompt
treatment for the initial infection but also lowers risk for subsequent infections.
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CHAPTER 1. INTRODUCTION
Overview
Health care associated infection (HAI) among patients in the intensive care unit
(ICU) has been identified as an independent risk factor for hospital mortality.1 Patients
presenting to the ICU are at high risk for development of HAI 2 which can result in
prolonged ICU stay, as well as sequelae leading to organ dysfunction and death.2-5 The
mechanism for development of all HAI is unclear; although, predisposing factors such as
invasive devices6-8 may be responsible for approximately half of all HAI9 and severity of
illness is a predisposing factor.9,10 Although the central role of the inflammatory
response is to control infections, an exaggerated response may also play a role in the
development of HAI.
Cytokines are proteins that orchestrate the inflammatory response. The
inflammatory response begins locally and may become systemic. There is usually a
balanced inflammatory response, with pro-inflammatory cytokines (i.e., IL-1β, TNF-α,
and IL-6) initiating the inflammatory process against infection, and anti-inflammatory
cytokines (i.e., IL-1ra and IL-10) functioning to down regulate the inflammatory
response.11 Systemic inflammation is usually manifested with fever or hypothermia,
tachycardia, hyperpnea, and leukocytosis or leukopenia.
Baseline severity of illness (measured by APACHE II) correlates with baseline
inflammatory response and this process is independent of the causative organism.12 The
relationship between the development of new HAI and the degree of baseline systemic
inflammation or severity of illness has not been fully explored in patients with sepsis.
Excessive inflammation has harmful effects and may be a contributing cause of HAI in
the ICU.
Sepsis is a complex disease involving a large number of genes. Several
polymorphisms have been well characterized in sepsis.13-19 Knowledge is accumulating
regarding the genetic susceptibility to infectious disease; however, gene-gene, geneenvironment, and host-pathogen interactions should also be considered.20-22
Identification of promoter polymorphisms is important when examining an exaggerated
inflammatory response. There are a number of important candidate polymorphisms that
may be involved in the development of HAI.
Specific Aims
The purpose of this study is to determine the impact of baseline systemic
inflammation (pro-inflammatory cytokine, anti-inflammatory cytokines, and their ratio),
genetic variability, and environment on the development of HAI among patients with
sepsis during their ICU stay. One of the primary goals of this study is to determine
whether exaggerated baseline systemic inflammation increases risk for development of
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HAI during ICU stay. If true, this recognition may promote earlier detection and
treatment of infections. Another goal of this study is to identify candidate genes involved
in susceptibility of recurrent infections (new HAIs) in sepsis. It is unknown if these genes
may differ from genes responsible for the sentinel sepsis event.
The specific aims were to:
1.

Investigate whether baseline protein expression levels of pro-inflammatory
cytokines, anti-inflammatory cytokines, or their ratios influence the development
of subsequent HAI in patients with sepsis.

2.

Investigate the variance in cytokine genes to determine if they influence levels of
protein expression or development of HAI.

3.

Investigate the effects of protein expression levels, genetic variation, and
environment on development of HAI.
Significance

The findings of this study may provide important new insights into risk factors
that contribute to the development of HAI in patients presenting to the ICU with sepsis. It
is possible that these findings may be relevant for all patients who develop HAI, as
patients may develop sepsis as the result of developing HAI. Targeting early exaggerated
inflammation and increased severity of illness may allow earlier detection of HAIs, and
promote earlier diagnosis and treatment, perhaps reducing the cost of care (by reducing
hospital length of stay) and sequelae that lead to organ dysfunction and death. Thus, these
findings may impact nursing and other critical care clinician practice first by helping to
identify patients at risk, then implementing stricter targeted infection control practices in
efforts to prevent development of HAIs (in addition to current standard and
recommended practices), and lastly in early recognition and treatment when HAI occur.
Conceptual Model
The effects of sepsis and severe sepsis are far-reaching, with severe sepsis
affecting approximately 751,000 annually in the US, with a 29-38% mortality rate.23 It is
unclear how many of these cases represent new HAI (sepsis occurring at least three days
after hospital admission) versus those who were admitted to the hospital or ICU with
sepsis. Patients admitted with sepsis seem to be at higher risk for development of
HAI.3,4,24 An appropriate immune response to an infectious insult 25 as well as early
intervention of appropriate antibiotics, fluid resuscitation, and supportive care26-28 are key
to a favorable outcome in sepsis. Sepsis is the clinical manifestations of an infectious
insult and was defined by Consensus Conference in 1992.29 These definitions are still
commonly used by clinicians today, and their usefulness was reaffirmed by international
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experts attending the 2001 International Sepsis Definitions Conference, who also
proposed a new staging classification system using the acrostic PIRO (P=predisposition,
I=insult infection, R=response, O=organ dysfunction), similar to the TMN approach used
for tumor staging, to better characterize sepsis.30-34 Use of the PIRO model has been
described as an effective classification system for researchers given the diversity and
heterogeneity of patients with sepsis.35 Aspects of this system were incorporated into the
conceptual model.
The conceptual model for the development of HAI in sepsis (Figure 1-1) is very
complex; yet, this map represents a simplified depiction and incorporates the work of
others.4,31-33,35 The infectious insult, predisposing factors, severity of illness, and
inflammatory response are all key factors to understanding the development of HAIs.
Definition of Terms
The following terms and definitions are provided for the major concepts in the
model. These were the operational definitions used for this study.
Elements of Sepsis
•

Systemic Inflammatory Response Syndrome (SIRS): The presence of at least
two of the following: temperature > 38°C or < 36°C, minimum heart rate ( >
90 per minute), elevated respiratory rate > 20 per minute) or a PaCO2 of < 32
mmHg, and an abnormal white blood cell count ( >1 2,000 or < 4,000 cells
μL−1) or bandemia ( > 10%).29

•

Sepsis: SIRS with an identified or suspected source of infection.29

•

Severe Sepsis: The manifestation of sepsis with organ dysfunction.29

•

Sequential Organ Dysfunction Assessment (SOFA): The SOFA was used to
assess the degree of organ failure among participants. The SOFA score
include assessment of six organs (Respiratory, Coagulation, Liver,
Cardiovascular, Central nervous system, and Renal). The score for each organ
ranges from 0 to 4, with a total SOFA score ranging from 0 to 24.36

•

Multiple Organ Dysfunction Score (MODS): The MODS score is an
alternative approach for assessing these 6 organs assessed by SOFA.37 For
this study the MODS is used to measure of the number of organs with
clinically significant organ dysfunction (range 0 to 6). Similar to the SOFA
score, the MODS score also provides a range of categories based on organ
function from normal to extreme dysfunction. The cutoff for moderate
dysfunction is considered to be clinically significant organ dysfunction. One
point is assigned for each clinically significant organ dysfunction using the
3

Sepsis:
Infectious insult
plus systemic
inflammatory
response
syndrome (SIRS)

Predisposing Factor:
Invasive Devices
Genetic Predisposition
Environmental Exposure
Severity of
Illness:
APACHE II

Elevated
Cytokines

Inflammatory
Response
Gene Expression

Figure 1-1. Development of Health Care Associated Infections in Sepsis.
Note: This conceptual model incorporates the work of others.4,31-33,35
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HAI

following criteria for each organ: (A) Cardiovascular failure is defined by
systolic blood pressure less than or equal to 90 mmHg which is not responsive
to fluids; (B) Pulmonary failure is defined by a PaO2:FiO2 of 300 mmHg or
less; (C) Central nervous system failure is defined as a Glascow Coma Score
of 12 or less; (D) Coagulation failure is defined as a platelet count of 80,000
or less; (E) Renal failure is defined as a creatinine of 2 mg/dl or less; and (F)
Hepatic failure is defined as a total bilirubin of 2 mg/dl or less.37 to fluids; (B)
Pulmonary failure is defined by a PaO2:FiO2 of 300 mmHg or less; (C)
Central nervous system failure is defined as a Glascow Coma Score of 12 or
less; (D) Coagulation failure is defined as a platelet count of 80,000 or less;
(E) Renal failure is defined as a creatinine of 2 mg/dl or less; and (F) Hepatic
failure is defined as a total bilirubin of 2 mg/dl or less.37
•

Infectious insult: Any definitive or suspected infection present at ICU
admission will be described as a baseline infection. Suspected infections were
defined clinically by the healthcare team.

Elements of Severity of Illness
•

Severity of illness: An objective measure of each participant’s illness.

•

Acute Physiology and Chronic Health Evaluation II (APACHE II): A
commonly used severity of illness classification system designed to capture
the worst of 12 physiological variables within the first 24 hours of ICU
admission. APACHE II scores range from 0 to 71 with a higher scores
associated with a worse outcome.38 APACHE II will be used as a measure of
severity of illness in this study.

Elements of Predisposing Factors
•

Predisposing factors: Potential risk factors for development of HAI.

•

Invasive Devise: Any artificial device that bypasses the body’s first line of
defense, the integument, is considered an invasive devise. Common invasive
devices in this study include endotracheal tubes, tracheostomy tubes, central
venous catheters, peripheral venous catheters, arterial catheters, chest tubes,
surgical drains, nasal and oral feeding tubes, percutaneous endoscopic
gastrostomy tubes, and Foley catheters.

•

Genetic Predisposition: Increased susceptibility to a disease due to the
presence of one or more gene mutations, and/or a combination of alleles
(haplotype), that are associated with an increased risk for the disease.39 In this
study, single nucleotide polymorphisms (SNPs) will be used to detect genetic
variation among participants.
5

•

Single nucleotide polymorphisms (SNPs): A difference in a single DNA
nucleotide which can be measured and may be associated with disease.39

•

Environmental Exposure: Any potential exposure in a patient’s environment
that could introduce an infection. In this study, environmental exposure
includes invasive devices, nurse-patient ratios > 2:1, and administration of
blood products. Universal precautions are expected to be followed on all
subjects and this includes appropriate hand-washing, protective equipment
use, and aseptic technique to prevent cross-infections.

Elements of Inflammatory Response
•

Gene Expression: The process of translating genes into a functional protein
product. For the purpose of this study, gene expression will be limited to
measurement of cytokine proteins by multiplex bead based assays.

•

Cytokines: Protein mediators of the inflammatory response.

Health Care Associated Infections
•

Health care associated infection refers to any infection that occurs after at
least three days of hospitalization which is not a recurrence of the baseline
infection.

•

Specific HAIs are defined by CDC guidelines as described in the methods
section. The operational definition for this study will include NEW HAIs that
occur after at least three days of admission to the ICU which are not a
recurrence of the baseline ICU infection.

•

HAI that occur up to 48 hours after ICU admission are considered to be ICU
related HAI.
Assumptions

The following assumptions were made for the purpose of the study:
1.
2.
3.

An underlying assumption of this study is that baseline systemic inflammation
will be prolonged.
HAI will be detected when they occur.
Subjects will be classified correctly in analyses based on degree of baseline
systemic inflammation and development of HAI.
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Potential Limitations
This study included the following potential limitations:
1.

The usage of corticosteroid therapy may impact the degree and duration of
systemic inflammation; thus, potentially limiting the possible impact of systemic
inflammation on the development of HAI in participants receiving corticosteroids.

2.

The use of corticosteroids may limit fever among participants experiencing HAI,
and may result in failure to detect HAI when they occur. It is recommended
clinical practice in our ICU to use sepsis surveillance, and thus a high degree of
suspicion when steroids are used.

3.

There may be predisposing factors for development of HAI that were not
measured.

4.

Participants receiving mechanical ventilation may have lower DNA yields from
buccal swabs due to the presence of a large obtrusive bite block which limited
access to swab the inside of the entire cheek as recommended.

5.

The investigator is a novice bench researcher, and although efforts were made to
accurately follow protocols, it is possible that errors could have influenced results.

6.

Endpoint genotyping of the single nucleotide polymorphisms RS1800896
required manual calls in seven samples.

7.

Interleukin 6 was selected as a proinflammatory cytokine; however, it does have
some anti-inflammatory properties.
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CHAPTER 2. BACKGROUND
Background and Significance
Health care associated infections (HAI) affect more than 2 million persons
annually in the US, with approximately 35% occurring in the ICU. A 1999 Institute of
Medicine report attributed 44,000-98,000 annual deaths and the associated cost was as
high as $29 billion.40 HAIs (or hospital acquired infections) are typically referred to as
infections that are not present or incubating at the time of hospital admission. Infections
are “considered to be hospital-acquired if they develop at least 48 [hours] after hospital
admission without proven prior incubation.”40 Common HAI’s in the ICU are
bloodstream infection, pneumonia, and urinary tract infections. Despite standard
practices to prevent them, HAIs remain a significant public health care concern.
HAI Incidence and Infection Patterns
Rates of infections vary but the most common hospital infections in descending
order are urinary tract infection, surgical wound infection, lower respiratory tract
infection, bacteremia, and others.41 Infections are generally classified as primary or
secondary and the source may be endogenous or exogenous.41 The National Nosocomial
Infections Surveillance (NNIS) System collects surveillance information across medical
intensive care units in the United States. An analysis of NNIS data (n = 181,993)
determined the most frequent types of HAI in the ICU were urinary tract infections
(31%), pneumonia (27%), and primary bloodstream infection (19%) from surveillance
data between 1992 and 1997.42 The most common pathogens reported were Coagulatenegative Staphylococcus, Staphylococcus aureus, and Enterococcus spp. The authors
provide a comprehensive summary with percentages for each type of infection.
In contrast to the pattern of infections among all US ICU patients, a one day ICU
prevalence study conducted in 1992 provides a similar pattern of infection types
occurring in European ICU patients. In descending order, Vincent et al. reported the most
common ICU infection as pneumonia (46.9%), lower respiratory tract infection (17.8%),
UTI (17.6%), and bacteremia (12%) in a large European study of 10,038 subjects in
1,417 intensive care units with a total of 4051 infections.43 These authors reported the
most common organism as Enterobacteriaceae (34.4%) followed by Staphylococcus
aureus (30.1%), Pseudomonas aeruginosa (28.7%), Coagulate-negative Staphylococci
(19.1%), and fungi (17.1%). Organisms were not reported for each type of infection
separately.43
In a more recent study of a combined medical and surgical ICU, the most frequent
infections (in descending order) were ventilator associated pneumonia, surgical site
infection, lower respiratory tract infection, intrabdominal infection, sinusitis, soft tissue
or skin infection, bacteremia, and finally, UTI.2 This study examined risk factors for
mortality and organisms were not provided. The pattern of infections in the ICU varies.
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The rates of NI may vary widely depending on the type of ICU and population served.
Eggiman and Pitet provide a comprehensive list of infection rates by type of ICU.40 The
causative organism may not be detected in all infections and the rate of viral infections in
the ICU may be underappreciated. There is evidence that despite causative organism type
(gram negative, gram positive, polymicrobial, or fungal) the host’s inflammatory and
coagulation response is similar in severe sepsis.12
Antimicrobial Resistance
Several factors in the ICU contribute to promoting antimicrobial resistance. These
include (1) cross-transmission often caused by the urgency of care that may result in
inconsistent aseptic technique or hand washing, (2) compromise of host defenses through
the use of invasive devices which may become colonized, (3) the use of antibiotics.44
The emergence of antibiotic resistant organisms such as Methicillin resistant
Staphylococcus aureus (MRSA), Vancomycin resistant Enterococcus, and other
multidrug resistant organisms are major concerns.44-47 Caution in antibiotic prescribing in
both the community and hospital setting has been advised. Only approximately 30% of
antimicrobials used in hospitals are being given as definitive therapy for known infection
associated pathogens based on microbiologic susceptibility.44 Cycling empiric
antimicrobial therapy has been proposed to reduce antimicrobial resistance and has had
favorable results in the susceptibility profile of gram positive but not gram negative
organisms.48,49
The concept of antibiotic cycling to reduce antimicrobial resistance has been
around since at least 1986.50 Since microorganisms are generally adaptive to their
environment, limiting the introduction of particular antimicrobial for periods of time may
help to decrease resistance patterns. There are few controlled trials published. A number
of methods have been proposed to assist with cycling including the use of hospital
formularies.51 The use of local antibiograms should be used to guide empiric therapy and
antimicrobial therapy should be guided by susceptibility testing as soon possible since a
delay in appropriate antimicrobial therapy worsens outcome. Antibiograms are
frequently used to adjust antibiotics in the ICU; however, failure to use them in other
settings is a contributor to antimicrobial resistance.52
Risk Factors for Developing HAI
Patients admitted to the ICU have an increased risk for developing HAI which
may be related to underlying disease conditions, impaired immunity, invasive devices,
inappropriate aseptic technique, or secondary infections after broad spectrum antibiotics.2
Eggimann identifies severity of illness, prolonged length of stay, and vascular access as
independent risk factors for the development of HAI. He provides a thorough review of
infection control practices in the ICU, and attributes most infections to inadequate
infection control practice, and also implicates understaffing and overcrowding of the ICU
as contributing factors.40 Genetic susceptibilities are known to increase the risk of
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developing infections;20,21 however, the influence of these genetic susceptibilities on
development of subsequent HAI is unknown. Recommendations for standard practices to
prevent the development of HAIs in the ICU have been reported by the Infectious
Disease Society of America (IDSA), the Center for Disease Control (CDC), and
others.53-57
Role of the ICU Environment and HAI
As noted in the prior sections, being a patient in the ICU presents several inherent
risks factors for the development of HAI including: presence of invasive devices, use of
broad spectrum antibiotics, use of blood products, and generally more physical contact
with the health care team administering care. A standard patient to nurse ratio for most
critical care units is 2:1 depending upon patient acuity. The implementation of open
visitation in the ICU has the potential to introduce additional risk of cross-contamination
to this vulnerable population. Appropriate hand hygiene is essential to prevent crosscontamination, in addition the CDC reports the potential role of HAI transmission by
health care provides wearing rings and long or artificial nails.58 Routine isolation
practices are used when any multi-drug resistant organism is detected.59 The floors are
mopped and cleaned daily as well as between patients according to CDC guidelines.60
The areas closest to the patient including the bed side rails, bed controls, bedside tray,
and call light are typically only cleaned between patients unless soiled and may represent
items that needs to be targeted for more frequent cleaning.
Severity of Illness
Severity of illness can be quantified by using the Acute Physiology and Chronic
Health Evaluation (APACHE) II, a composite score that ranks a patient’s worst
physiologic functioning within the first 24 hours of ICU admission.38 The APACHE II is
in the public domain and was used for this study. Severity of illness has been investigated
as a risk factor for developing HAI. Girou et al, conducted a retrospective case-control
study (n = 82) with 1:1 matching based on initial severity of illness using APACHE II
and also obtained serial APACHE II scores to determine the influence of severity of
illness on development of infections. Among several variables assessed, they identified
day three APACHE II score as significantly higher in the cases (p = 0.04).61 All patients
had similar APACHE II scores at baseline, and worsening of APACHE II score provides
evidence of worsening severity of illness among those who developed HAI. In contrast,
Vincent et al, in a one day prevalence study across 17 European ICUs (n = 10,038),
identified a high APACHE II score of greater than 31 to be independently associated with
risk of mortality; however, they reported the highest HAI rates in patients with APACHE
II scores ranging from 11-20.43
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Invasive Devices
Invasive devices bypass the body’s first line of defense, the integument, and may
lead to infection if penetrating organisms are not promptly sequestered by the innate
immune system.25 Common invasive devices in the ICU include endotracheal tubes,
central venous catheters, peripheral venous catheters, arterial catheters, chest tubes, nasal
feeding tubes, and Foley catheters. Several studies have been published describing the
relationship between invasive devices and infections.8,40,42,53,62-64 In many cases HAIs
are used as a benchmark for quality of care, and Maki suggests that peripheral
intravenous catheters (previously considered low risk) should begin to be targeted by
infection control practices to reduce invasive device related infections.64 The use of
antibiotic impregnated devices and targeted strategies have helped to reduce the rates of
invasive devise related infections.65,66
Invasive devices may be colonized with bacteria or fungi through biofilm
formation. Biofilms generally forms when microorganisms adhere to invasive devices
which provide them with an environment capable of evading antibiotics. They initially
adhere to the foreign surface and then begin to secrete extracellular polymeric substance
(EPS) to protect formation of the biofilm and attract other organisms. The
microorganisms within a biofilm exhibit different physiologic and growth characteristics
than do free floating (or planktonic) organisms.67 They use quorum sensing to
communicate and control the gene expression of other organisms within the biofilm, and
to control each phase of biofilm formation: attachment, cell-to-cell aggregation,
proliferation, EPS production, grown, and detachment or degradation.68 Acute infections
are generally caused by the planktonic (free floating micro-organisms) but the role of
biofilm formation on chronic and acute infection is an area of research.67,69,70
Systemic Inflammatory Response Syndrome
The body is subject to a variety of insults daily and the immune system is usually
able to isolate and clear potential pathogens without systemic effects. When the body is
not able to maintain inflammation at the local level, inflammation becomes systemic. The
systemic inflammatory response syndrome (SIRS) is the clinical manifestation of the
body’s host defense response to a variety of insults and initially manifests in at least two
of four major organ systems (cardiovascular, hematopoietic, neurologic, and respiratory
system). These insults can be infectious or noninfectious in nature. Noninfectious insults
include pancreatitis, burns, trauma, tissue ischemia or necrosis, massive transfusion,
chemical aspiration, foreign bodies, and immune hypersensitivity reactions.29,71,72
The goal of the inflammatory response is to control the initial insult or injury.
Three primary responses (vascular, neutrophil, and plasma protein) function to increase
blood flow to the affected area, increase vascular permeability to allow leukocytes and
plasma proteins into the site of injury or infection.71 SIRS is a dysregulated
inflammatory response caused by activation of inflammatory cells. It is a generalized
response regardless of the type of insult. This dysregulated inflammatory response leads
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to generalized systemic inflammation, damaged vascular endothelium, altered immune
function, fluid shifts, and organ hypoperfusion.71 If this process is not controlled, it can
progress to multiple organ dysfunction syndrome.71 SIRS occurs in approximately one
third of all hospitalized patients and one half of ICU patients.71
Cytokines
Cytokines are produced by a variety of cells (lymphocytes, macrophages,
epithelium, endothelium, connective tissue, adopocytes, and myocytes) which modulate
the function of other cell types.72 Cytokines are pleotropic which means that one cytokine
can act on a number of cell types and have many effects.73 They have autocrine,
paracrine, and endocrine effects. Cytokines play a role in both acute and chronic
infections.72 Activated lymphocytes and macrophages are their primary secretor.
Cytokines are not stored in their active states in the cell. Their production requires new
mRNA and protein synthesis. Most are encoded as pro-peptides, transported to the Golgi
body for glycosylation, and secretion as smaller mature cytokine proteins.74
A growing number of cytokines are still being discovered. Interleukins mediate
communication between leukocytes. IL-1β and TNF-α promote the acute inflammatory
response, thus they are typically referred to as pro-inflammatory cytokines. IL-6 is
another potent inducer of the acute inflammatory response. It stimulates the liver to
release acute phase proteins. Although IL-6 is often referred to in the literature as a proinflammatory cytokine, evidence is accumulating regarding its’ anti-inflammatory
properties. IL-6 inhibiting effects of IL-1β and TNF-α.75 IL1-ra and IL-10 are both
know as anti-inflammatory cytokines. Table 2-1 summarizes the function of well known
pro- and anti-inflammatory cytokines.
HAI Risk Posed by the Inflammatory Response
There is some evidence that cytokines may enhance extracellar and intracellular
growth of bacteria76-79 and that anti-inflammatory cytokines may promote the
development of infections.11,80 Kanangat et al. found, in an in vitro model, that
monocytes that were primed with higher levels of proinflammatory cytokines
experienced higher levels of intracellular bacterial growth; whereas monocytes primed
with lower levels of proinflammatory cytokines experienced lower levels of intracellular
bacterial growth.77 In another in-vitro study, Kanangat also found that cytokines
enhanced the extracellular growth of Staphylococcus aureus.76 Because of the complexity
of the inflammatory response which includes redundancy of the inflammatory networks,
competing feedback loops, and simultaneous amplification pathways35, it is uncertain that
a relationship that exists in-vitro will exist in-vivo.
It is possible that high levels of cytokines function as bacterial growth factors76-79
or that anti-inflammatory cytokines may promote the development of infections.11,80 It is
also possible that an exaggerated inflammatory response may promote HIAs by inhibition
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Table 2-1. Summary of Cytokine Function.
Cyokine

Function

Reference

IL-1β

Mediate innate immunity. T cell activation.
Macrophage activation. Fever. Induces production of
IL-6. Induce endothelial adhesion molecules.

TNF-α

Mediate innate immunity. Local inflammation.
Induces acute inflammation by activation of and
endothelial cells. Induce endothelial adhesion
molecules. Activates macrophages and inducted
nitric oxide production. Fever. Mobilization of
metabolites. Shock.

IL-6

Mediate innate immunity. Acute phase protein
production. Fever. T and B cell growth and
differentiation. Activates T and B cells. Downregulates the synthesis of IL-1 and TNF.

IL-10

Potent suppressor of macrophage functions by
inhibiting cytokine release. Inhibits TH1 cells. Effects
B cells to increase MHC class II. Down regulate the
immune response. Deactivates monocyte/macrophage
proinflammatory cytokine synthesis.

IL-1ra

Inhibits IL-1 by binding to the receptor by
competitive inhibition of the receptor IL-1 site.

25,73,81

25,73,81

25,73,75,82

25,73,75

25,75

Note: IL denotes interleukin. TNF denotes tumor necrosis factor. IL1ra denotes IL-1
receptor antagonist. MHC denotes major histocompatability complex. T cells are T
lymphocytes that were derived from the thymus. B cells are B lymphocytes that were
derives from bone marrow. TH1 denotes a class of T helper cells.
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of Toll-like receptors (TLRs)83 or by impairment of neutrophil function.84 Toll-like
receptors are a family of proteins that act as pattern recognition receptors and enable cells
to recognize pathogen-associated molecular patterns. TLRs allows the innate immune
system to immediately recognize highly conserved bacterial, viral, and fungal
components.83,85 An evolutionary mechanism that evolved to protect the host from the
harm of an overly responsive immune system, such as exaggerated IL-6 levels, is the
inhibition of Toll-like receptor signaling by IL-1 receptor associated kinase-M.86 High
IL-6 levels have also been reported in a small study (n = 21) of patients with HAIs who
had impairment of neutrophil function resulting in impaired phagocytosis and bacterial
killing.84 If the relationship of exaggerated or high IL-6 levels and development of HAIs
is confirmed in this study, the underlying mechanism will require investigation.
There have been no clinical studies to determine how cytokines influence
bacterial growth in sepsis. However, in 1997, Headley et al. studied the effect of
infections and the inflammatory response in ICU patients (n = 34) with Acute Respiratory
Distress Syndrome (ARDS). They found that the outcome in ARDS was not related to the
development of HAIs but that it was attributed to the magnitude and duration of the
inflammatory response. It is unclear if they specifically tested the association of baseline
level of inflammation and development of subsequent HAI. One important finding was
that when a new HAI developed, it was not accompanied by an increase in levels of
inflammatory proinflammatory cytokines.87 The same authors have reported in the past
that persistent elevation of inflammatory cytokines was a poor predictor of outcome. The
authors provided evidence that non-survivors have high levels of inflammatory cytokines
at baseline which persisted for at least the first 10 days, whereas, survivors had a lower
baseline level which decreased over the first 10 days.88 It is unknown how long this
relationship persists since data were not shown beyond 10 days. A similar persistent
elevation of the pro-inflammatory cytokine, IL-6, was recently reported in non-survivors
with severe sepsis.89 The first week to 10 days may describe a more homogenous
population of early infections; however, infections may also be described as early,
middle, and late infections.90 The relationship of persistent systemic inflammatory,
when defined clinically as systemic inflammatory response syndrome (SIRS) and not
based on cytokine levels, has been shown to significantly increase the risk for developing
HAI in a trauma population.90,91
The relationship of severity of illness and health care associated infections has
been described.10 McCluster et al. similarly report that patients who developed HAI had
higher APACHE III scores than those who did not develop HAI but the relationship was
not statistically significant.9 Kinasewitz et al. analyzed multiple biomarkers from the
PROWESS data set (n = 1,690), a randomized controlled trial of recombinant human
activated protein C in severe patients with sepsis. They found significant correlations in
biomarkers relative to increasing levels of APACHE II. Of interest, median and
interquartile ranges of IL-6 (pg/ml) were increased for all participants with an increase
for each quartile of APACHE II (1st quartile: 289 (245 - 369), 2nd quartile: 384 (322 489), 3rd quartile: 623 (494 - 829), 4th quartile: 1043 (809 - 1613), p < 0.001). Their data
for IL-10 (pg/ml) was inconclusive as 59% were below the detection limit: (1st quartile:
≤ 10 (10 - 10), 2nd quartile: ≤ 10 (10 - 10), 3rd quartile: ≤ 10 (10 - 30), 4th quartile: ≤ 10
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(10 - 27), p = 0.001).12 The APACHE II ranges for each quartile were: 1st quartile (3
- 19), 2nd quartile (20 - 24), 3rd quartile (25 - 29), and 4th quartile (30 - 59). Criteria for the
original study included severe sepsis with at least three signs of systemic inflammation
and at least one organ failure.92
It is assumed that patients with sepsis who present with a high degree of baseline
systemic inflammation will have persistent inflammation which may contribute to the
development of HAI. The role of pro- versus anti-inflammatory cytokines in the
development of sepsis is an area of debate. Assessment of the cytokine profile may be
more predictive than assessing individual cytokines in isolation.93 Although other more
common mechanisms for the development of HAI exist, such as poor aseptic techniques,
the relationship of systemic inflammation and development of HAI in patients with sepsis
presents a novel approach which is explored in this dissertation.
Rationale for Selecting IL-6 and IL-10
When planning this dissertation study, it was to be limited it to one proinflammatory cytokine, one anti-inflammatory cytokine, and one ratio. Before this project
began, there was concerned about the use of IL-1β and IL-1ra due to reports of low
detection limits in the literature. In addition to measuring IL-1β and IL-1ra, we also
measured TNF-α, IL-6, and IL-10. IL-6 and IL-10 were included as an alternative pro- to
anti- inflammatory ratio since they were less likely to be below detection limits and
because there were other reports examining these ratios.94 A large number of cytokine
values were below the detection limit for IL1B (66 or 84%) and IL1ra (50 or 64%) which
indeed limited comparison of their ratios. These low detection limits also limited our
ability to detect a difference in cytokine levels for the associated SNP. It is probable that
these very low concentrations (below the 3.2 pg/ml threshold used in this study) are
biologically important, despite the fact that they cannot be precisely measured. A total of
5 (6.4%) IL-6 levels and 29 (37.2%) IL-10 levels were below the detection limit.
Numerous articles throughout the literature include IL-1β, TNF-α, and IL-6 as
pro-inflammatory cytokines; however, it should be noted that IL-6 also has many other
functions. IL-6 not only induces the acute phase response causing the liver to release
CRP and other acute phase reactants, it is also involved in immunoglobulin switching
necessary for acquired immunity.95,96 IL-6 may have a protective effect against
development of septic shock;96 whereas, minute amounts of TNF- α and IL-1β are potent
initiators of septic shock.81 IL-6 has been shown to consistently correlate with clinical
severity of inflammation, autoimmune, and infectious disease; whereas, this relationship
is not always clear with IL-1 and TNF.97 IL-6 levels have been used to predict fatal
outcome in septic shock whereas this has not been shown with TNF levels. Dinarello
concludes that among patients with septic shock, IL-6 levels seems to “represent the net
effect of biologically active IL-1 and TNF”.97
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Sepsis Polymorphisms
Sepsis is a complex disease involving a large number of genes. Genes are
composed of deoxyribonucleic acid (DNA) which is a polynucleotide chain made from
sugar (2-deoxyribose) linked to phosphate backbone with protruding nucleotide bases.
These bases are either purines (Adenine and Guanine) or pyrimidines (Cytosine and
Thymine). A polymorphism is a common variation (greater than one percent) in the DNA
sequence among individuals; whereas, a mutation has a frequency of less than one
percent. A single nucleotide polymorphism is the substitution of one of the four
nucleotide bases with another nucleotide base and may confer a survival advantage.98
Another type of polymorphism is a tandem repeat or microsatellite polymorphism, in
which a number of nucleotides are repeated once or several times. The normal or usual
genotype is referred to as the wild type, although wild type can refer to the genotype or
phenotype.99
Only about 10 percent of the DNA sequence in the human genome codes for
genes, and SNPs occur approximately every 1,000 base pairs with most not resulting in a
protein or secretion change.98 SNPs occurring in the promoter regions of genes have
potential to influence the level of gene expression and are likely to be important. Several
polymorphisms have been well characterized in sepsis.13-19 Knowledge is accumulating
regarding the genetic susceptibility to infectious disease; however, gene-gene, geneenvironment, and host-pathogen interactions should also be considered.20-22
Identification of promoter polymorphisms is important when examining an
exaggerated inflammatory response. There are a number of important candidate
polymorphisms that may be involved in the development of HAIs. Table 2-2 includes a
brief review of selected polymorphism. Although evidence supports the importance of
these polymorphisms in sepsis, a study of young, healthy white males with no smoking or
co-morbidity history, found a trend but no clear association between common
polymorphisms and cytokine levels in a sepsis model of endotoxin exposure.100 There is
research indicating that epigenetic factors may down regulation genes as early as 3-5
hours after an infectious insult which could be the reason the investigators did not find an
association.101 It is reasonable to conclude that patients who have already shown
susceptibility to sepsis by presentation to the ICU with sepsis have a different risk profile
than these healthy young men. Additionally, polymorphisms in one cytokine gene may
enhance expression levels of other cytokine genes.102
Cytokine Gene SNPs for IL-6 and IL-10
The gene for IL-6 is located on chromosome seven on the p arm. The gene for IL6 consists of 4,856 nucleotides and begins at location 22,766,766. The promoter region
lies upstream from the gene. It generally starts approximately 25 bp upstream from the
gene starting point but transcription factors have a large “footprint” and their binding to
the promoter is necessary prior to the binding of RNA polymerase II and ultimate
transcription of IL-6 into mRNA.103 There are several SNPs located within the promoter
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Table 2-2. Selected Cytokine Polymorphism Investigated in Sepsis.
Gene
Cytokine Location

Polymorphism

RS Number

Rationale

IL-1β

2q14

-511C/T

rs1143643

Mixed results.
Increased risk for
septic shock
(C/T).

TNF-α

6p21.3

- 308 G/A

rs1800629

A, increased risk
for sepsis

rs1800795

G, higher
cytokine levels,
others lower
levels

IL-6

7p21

-174 G/C

IL-10

1q31-q32

-1082 G/A

rs1800896

G, shock, more
severe sepsis,
more severe
pneumonia

IL-1ra

2q14.2

86-bp repeat

na

A2, increased
risk for sepsis

Reference
104-106

19,107

16,18,108

16,19,107

16,18,19

Note: IL denotes Interleukin. TNF denotes tumor necrosis factor. IL1ra denotes IL-1
receptor antagonist.
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region of IL-6. RS1800795, previously known as -174G/C, is located at 22,766,645 and
has been well described in the literature. It has been associated with both higher and
lower levels of IL-6 when position RS1800795 is encoded by G.16,18,108
The gene for IL-10 is located on chromosome one on the q arm. The gene for IL10 consists of 4891 nucleotides and extends from location 206,945,839 to 206,940,948.
The promoter for IL-10 lies upstream from the gene and SNP RS1800896, previously
known as -1082 G/A, is located upstream within the promoter region at 206,946,897. It
has been shown that the presence of a G at this position is associated with shock, more
severe sepsis, and more severe pneumonia.16,19,107
Figure 2-1 shows the location of these SNP upstream from the gene using the
National Center for Biotechnology Information’s (NCBI) new Sequence Viewer v.2.12.
HapMap Data for Genotypes
The International HapMap Project began in 2002 with the goal of providing
patterns of human DNA sequence variation to enable scientists to investigate genes
affecting health, disease, and response to drugs and environmental factors. The
HapMap Project is currently in its third phase, HapMap 3, which includes 1,301
samples from eleven human populations, and 270 of those samples originating from
prior phases.109 HapMap 3 included samples from African ancestry in Southwest USA
(ASW) and Utah residents with Northern and Western European ancestry (CEU) were
included. Tables 2-3 and 2-4 show the distribution. Note the difference between ASW
and Africans from Sub-Sahara. Courtesy: National Human Genome Research Institute.
Selection of Exclusion Criteria
This study was designed to examine systemic inflammation and its influence on
the development of HAI. Patients with a disease process know to decrease immune
function and those receiving certain immunosuppressants could confound findings on
HAI. This includes patients with cancer and human immunodeficiency syndrome. It also
includes patients on high dose corticosteroids or chemotherapy. Acute phase proteins are
secreted by the liver in response to inflammation; thus, patients with a liver failure (Child
Pugh Score of C or worse) were also excluded. While the elderly may be more
susceptible to infections due to a functional decline in cell-mediated immunity,110 we
opted not to exclude patients based on age so that this relationship could be examined if it
existed in this population.
Preliminary Studies
Until recently, there had been no clinical studies examining the relationship of
excessive baseline inflammation with the development of subsequent health care
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A.

B.

Figure 2-1. Promoter SNP Locations.
Note: The red down facing arrow in each image denotes the SNP location. Image A
shows the IL-6 gene and the location of rs1800795. Image B shows the IL-10 gene and
the location of rs1800896. Images obtained from NCBI’s new Sequence Viewer v.2.12.
Available from: http://www.ncbi.nlm.nih.gov/SNP/.
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Table 2-3. HapMap 3 RS1800795 Genotype and Allele Frequencies.
Population
CEU
ASW
YRI

Number
226
98
120

CC
0.319
0
0

CG
0.434
0.184
0

GG
0.248
0.816
1.0

Note: The ancestral allele is G. CEU represents Utah residents with Northern and
Western European ancestry. ASW represents African ancestry from Southwest USA.
YRI represents Africans from Sub-Sahara. Courtesy: National Human Genome
Research Institute.
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Table 2-4. HapMap 3 RS1900896 Genotype and Allele Frequencies.
Population
CEU
ASW
YRI

Number
226
98
120

AA
0.212
0.449
0.531

AG
0.513
0.429
0.389

GG
0.274
0.122
0.080

Note: The ancestral allele is A. CEU represents Utah residents with Northern and
Western European ancestry. ASW represents African ancestry from Southwest USA.
YRI represents Africans from Sub-Sahara. Courtesy: National Human Genome
Research Institute.
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associated infections. The investigator performed a retrospective 6 week feasibility study
in the ICU where this dissertation study subsequently occurred.24 Since cytokine
measurements were not clinically available, the relationship of baseline C-reactive
protein (CRP) to the development of HAI was examined. All patients admitted to the
MICU/CICU for 6 weeks beginning 1/1/08 were screened for inclusion. All subjects with
a CRP drawn within 24 hours of ICU admission were included. Baseline demographics,
CRP, diagnoses, SIRS, APACHE II, MODS, infections, and invasive devices were
recorded and all patient records were reviewed through ICU discharge for the
development of HAI. Comparisons were made among those who did and did not develop
HAI.
Among 69 patients admitted to the ICU during the study period, 27 patients had
CRP levels within the first 24 hours. Among the 27 patients included in this older (62.3
± 12.9), male (96.3%) heterogeneous population, the mean APACHE II score was 17.8
± 7.0; 25.9% required vasopressors, 59.6% had suspected or definitive baseline
infections, 40.7% required mechanical ventilation, and the median baseline CRP level
was 58.4 mg/dL with wide variation (range 3 - 548). Nine (33.3%) patients developed
HAI (total of 15 infections) with bacteremia and UTI being most common. There were no
significant differences in survival, baseline CRP, APACHE II , SIRS, MODS, or hospital
length of stay in those who did and did not develop NI. There was a trend (p = 0.10)
towards development of a difference in ICU length of stay (10.4 vs. 4.4) in those who
developed new HAI versus those who did not, respectively. Patients with baseline
infections were more likely to develop new HAI 8 (88.9%) compared to those who did
not present with an infection 1(11.1%), p = 0.04. Although this was a small sample, it
suggests increased susceptibility to new HAI in those who were admitted with sepsis.

22

CHAPTER 3. METHODS
Research Design
This study was designed as a prospective observational study to evaluate the
effects of baseline systemic inflammation as measured by cytokine levels on the
development of HAIs in patients admitted to the ICU with sepsis or suspected sepsis.
Baseline pro-inflammatory cytokine, anti-inflammatory cytokine, and their ratios, along
with a common single nucleotide polymorphism for each cytokine tested were examined
among patients with sepsis who did and did not develop subsequent HAIs. Approval for
human subject’s research was obtained from the Memphis-Veteran’s Affairs Medical
Center (VAMC) Institutional Review Board (IRB) and University of Tennessee Health
Science Center (UTHSC) IRB, as well as the VAMC’s Research and Development
committee.
Study Population
All patients admitted to the Veterans Affairs Medical Center’s Medical Intensive
Care Unit (MICU) were systematically screened for sepsis at admission. A sample size
of 78 subjects was required to detect a 30% difference (40% in those with high systemic
inflammation versus 10% in those with low systemic inflammation) in development of at
least one HAI during ICU stay (up to ICU day 28). This calculation was estimated for
patients with high baseline levels of systemic inflammation (pro-inflammatory cytokine
level within 4th quartile) versus patients without high levels of systemic inflammation
(pro-inflammatory cytokine level not within 4th quartile) with an 80% power given a 3:1
ratio.
Inclusion Criteria
The following two conditions were inclusion criteria:
1. Presence of Sepsis within 72 hours of admission to the ICU: Sepsis is defined
as systemic inflammatory response syndrome (SIRS) plus an identified or
suspected infection. SIRS is defined as at least two of the following: abnormal
temperature ( > 38°C or < 36°C), minimum heart rate ( > 90 per minute),
elevated respiratory rate ( > 20 per minute) or a PaCO2 of < 32 mmHg, and an
abnormal white blood cell count ( > 12,000 or < 4,000 cells μL−1) or bands >
10%.
2. Age 18 or older.
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Exclusion Criteria
The following four conditions were exclusion criteria:
1. Receiving Immunosuppressive agents such as chemotherapy or greater than 1
mg/kg of prednisone or equivalent dose within the past 3 months.
2. Other Immunosuppression: AIDS.
3. Liver Failure defined as Child Pugh category C or higher.
4. Lack of informed consent.
Procedures
This section includes study related procedures.
Summary of Procedures
A summary of all study procedures over time is included in Table 3-1. Procedures
included screening, informed consent, data collection, specimen collection, and specimen
analysis.
Screening
Efforts were made to screen all patients for inclusion and exclusion criteria who
were admitted to the medical intensive care unit (MICU). Rounds were systematically
made in the MICU and the principle investigator interacted with the MICU medial team,
nursing staff, and reviewed records to determine if patients met eligibility. A waiver of
informed consent was obtained from the IRB to allow for screening of patient records for
eligibility. Patient records included their electronic chart, nursing flowsheets, x-ray films,
and other pertinent reports needed to determine eligibility. The principle investigator
completed training in human subject’s protection prior to initiation of this research.
Informed Consent
Subjects who met inclusion criteria and had no exclusion criteria were approached
for informed consent. When subjects were too ill to provide their own informed consent,
then a legally authorized representative/surrogate decision maker was sought for informed
consent. All legally authorized representatives (LAR) who provided informed consent met
requirement established by VAMC-IRB (see Appendix D, Informed Consent). The LAR
designation used for this study was adopted from Tennessee State Law; however, a new
designation has recently been adopted based on the latest release of the Veteran’s Affairs
Research Handbook which further limits LAR in regards to HIPPA consent for research.
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Table 3-1. Study Procedures.
Days
1
x
x

Procedures
Screening for inclusion/exclusion
Informed consent
Data collection
Sepsis source and medical history
APACHE II
Health care associated infection
Invasive devices
Antibiotics, SIRS score, vital signs
Clinical and lab assessments
HAI preventive strategies
Adverse events
Plasma collection for cytokines
Buccal swab collection for DNA
Outcome assessment

x
x
x
x
x
x
x
x
x
x

2 - 28

ICU Discharge
(or Day 28)

x
x
x
x
x
x

x
x
x
x
x
x
x

Note: ICU denotes intensive care unit. SIRS denotes systemic inflammatory response
score.
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As of March 2011, the only authorized LAR will include only individuals appointed
under the Durable Power of Attorney for Health Care or a court-appointed guardian.
Data Collection
Baseline demographic variables were collected at ICU admission including age,
race, and sex. Baseline sepsis (SIRS plus infectious cause) were collected in addition to
descriptive variables surrounding baseline sepsis including the presence of organ failure
(SOFA and MODS) and severity of illness (APACHE II).
Several predisposing factors were collected. Baseline plasma IL-6 and IL-10
levels were measured as well as their associated SNPS ra1800795 and rs1800896,
respectively. Potential environmental exposures were also collected including invasive
devices, nurse-patient ratios > 2:1 for any 4 hour period each day, and administration of
blood products. The number and type of invasive device was recorded each day and the
cumulative invasive devise score was recorded at the time of HAI and ICU discharge.
Duration of ICU stay was collected.
Patients were followed through their ICU stay (or up to 28 days) for the presence
of HAI based on CDC guidelines. Descriptive variables surrounding the first HAI were
recorded including SIRS and organ failure (SOFA and MODS).
In addition to the primary variables a number of other variables were collected to
better characterize the sample including vital signs, SIRS score, clinical triggers, all
cultures, standard of care laboratory tests, standard of care CXRs, antibiotic use, use of
steroids, and HAI preventive strategies.
Data were collected by the principle investigator using standardized forms which
were updated during the data collection process (see Appendix E). Information about
adverse events (primarily deaths) occurring during the study period were collected and
reported to the IRB. The occurrence of life threatening arrhythmias and respiratory and
cardiac arrests were also recorded. Data collection after ICU discharge was limited to 48
hours after ICU discharge for assessment of HAIs that could be attributed to ICU stay.
Reliability and Validity of Common ICU Measures
Vital signs are routinely recorded hourly in the ICU unless otherwise indicated.
The values recorded by the critical care nurses during the course of standard patient care
were reviewed. There was some variability in these measures and it was observed that
respiratory rate was sometimes collected from the EKG respiratory lead (where it is
captured and retained by the monitor) rather that from the ventilator display. There were
instances of respiratory rates recorded that were lower than the ventilator set rate. When
this occurred, the set ventilator rate was recorded as the minimum respiratory rate rather
than the rate recorded on the flowsheet. Calculation of APACHE II requires the highest
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or lowest values within the first 24 hours, along with the worst lab values in this time
period. The MICU uses bedside monitors with automated blood pressure cuffs which
will provide for consistency in blood pressure readings. Arterial lines and central lines
were routinely calibrated and maintained by bedside nurse per hospital policy. Standard
quality control procedures in the hospital’s laboratory include calibration of equipment at
least every 8 hours and as needed. During the course of this study, Exergen’s Temporal
Scanner TAT-5000 Temporal Artery Thermometer became routine use in the MICU.
There were no pilot studies to test the reliability or consistency of this method and it may
have introduced some bias in temperature measurement, and therefore SIRS scores.
Data Entry
Participant records were examined prior to data entry to assure that data
collection was complete. Clinical data were entered into a FilemakerPro® database.
Prior to data analysis, data was exported to Excel, and all data was reviewed and cross
checked for accuracy. Corrections were made to provide the most accurate dataset
possible. Laboratory data (cytokine measures) were imported directly into Excel from the
Luminex machine. Data from the LightCycler® 480 Instrument were also imported to
Excel for data analysis. Tests that did not meet specified conditions were repeated, and
excel spreadsheets were updated to reflect additional results.
Measurements
This section provides detail for study measurements.
Health Care Associated Infections
A HAIs were defined as any infection occurring after day 3 through ICU
discharge (or day 28 in participants with a prolonged ICU stay), excluding recurrent
positive baseline infections. All participants were monitored with equal diligence for the
development of HAIs daily through ICU discharge (or day 28 in participants with a
prolonged ICU stay). Participants who were discharged from the ICU prior to day 28
were followed for 48 hours in the hospital. All infections that occur up to 48 hours after
ICU discharge were also considered ICU related infections, just as infections occurring
within 48 hours of hospital admission are considered community acquired. If a
participant was readmitted to the ICU within 48 hours of ICU discharge, the patient was
followed as though their ICU stay had been continuous.
All culture results during the study period were recorded. Developing an HAI
during ICU stay was the primary outcome measure in this study. Each patient was
classified as either having or not having a definitive HAI during ICU stay by culture
criteria as defined below. Furthermore, the timing to development of first HAI was also
recorded. The specific type of HAI and causative organism were recorded. Borderline
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HAIs were adjudicated by pulmonary and critical care consultation. HAIs were recorded
in such a manner to allow for future incidence density calculations. The number and type
of devices were recorded daily for each subject.
This study was implemented using the most recent HAI definitions by CDC
Guidelines at that time.111 In November 2008, new HAIs guidelines replaced existing
guidelines.112 These new guidelines implemented minor changes in HAI definitions but
required that the new term “heath care associated infections” replace the prior term
“nosocomial infections”. Additionally, the names of common HAI have been updated to
reflect the new guidelines. The operational definition for each type of infection did not
change. Health care associated infections were defined by CDC Guidelines111 as follows,
and terms were revised to meet current guidelines:112
•

Bloodstream infection (formerly bacteremia) was defined by the presence of
a microorganism cultured from blood which is not related to another site of
infection. At least one blood culture is required to be positive, and when the
identified organism is a potential skin contaminant such as coagulase-negative
staphylococcus, two or more blood cultures must be positive.

•

Pneumonia was clinically defined as the presence of fever ( > 38◦C),
leukopenia ( < 4,000 WBC/mm3) or leukocytosis ( > 12,000 WBC/mm3), and
new or worsening infiltrate on CXR (or the presence of consolidation or
cavitation), and at least two of the following: (1) new onset of purulent
sputum, or change in sputum of change increased respiratory secretions, or
increased suctioning requirement, (2) New onset of worsening cough, or
dyspnea, or tachypnea, (3) Rales or bronchial breath sounds, or (4) worsening
gas exchange, increased oxygen requirements, or increased ventilation
demand. Pneumonia was also definitively defined by positive bronchial
alveolar lavage (BAL) with at least 104 cfu/ml.

•

Urinary tract infection (UTI) can be either symptomatic or asymptomatic.
Symptomatic UTI is defined as a positive urine culture with > 105
microorganisms/ml and one of the following: fever ( > 38◦C); frequency;
dysuria, loin pain; loin/suprapubic tenderness. A culture count of > 103
microorgansims may be considered significant if obtained from a suprapubic
puncture or in the presence of an antibiotic. It should be noted that many
critical care patients may not be able to communicate their symptoms and
steroids may results in failure to exhibit fever; therefore, culture counts of >
105 microorgansims in a urine culture obtained from an indwelling Foley
catheter were considered to be urinary tract infections. Other infections of the
urinary tract include presence of an abscess by direct observation during a
surgical procedure.

•

Sinusitis was defined by organisms cultured from the sinus cavity with the
presence of radiographic changes. In addition, one or more of the following
symptoms with no other recognized cause may be present: fever (> 38◦C),
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pain or tenderness over the involved sinus, headache, purulent exudate, or
nasal obstruction.
•

A Cardiovascular system infection –VASC (formerly catheter-related
infection) was defined as at least 15 colonies by semi-quatitative culture from
an intravascular cannula tip in the presence of fever ( > 38◦C), pain, erythema,
or heat at involved vascular size regardless of blood culture results.
Additionally, a catheter related infection can be diagnosed if purulent drainage
was present at the vascular site. It should be noted that many critical care
patients may not be able to communicate their symptoms and steroids may
results in failure to exhibit fever.

In addition to infections that are definitive (evidence by positive cultures), it is
possible that a patient may have had an infection that is not detected by culture. All
patients were followed prospectively. In the absence of positive cultures, a high degree
of clinical suspicion of infection which is treated and improves with an antibiotic was
recorded. New fever in the ICU can be infectious or non-infectious, thus it is standard
practice that any new fever is carefully investigated by the critical care team.54 All
potentially non-definitive infections were reviewed with a critical care clinician. Primary
analysis will include only definitive infections.
Invasive Devices
The presence of invasive devices was recorded daily through ICU discharge (or up
to 28 days for participants with a prolonged ICU stay). Invasive devices include
endotracheal tubes, central venous catheters, peripheral intravenous catheters, arterial
catheters, chest tubes, nasal feeding tubes, Foley catheters, and other drains or catheters
that have been inserted. A total daily invasive devise score as well as a cumulative daily
score will be calculated for each patient. Each invasive devise will be given a score of 1.
For example, if a patient has three invasive devices for days 1-5, then only one device for
days 6-14, then their daily score will be 3 for the first five days and 1 for subsequent
days. On day 14, the cumulative score will be (3*5 + 1*9) = 24. A cumulative score for
each day of the study will provide an estimate of their total exposure to invasive devices
at any given time during the study period. This is a novel way to examine invasive
devices and may be important since infections that occur early (day 5) will have less
exposure to invasive devices than those that occur later. The invasive device score to be
used in the regression model will be the invasive device score at the time of first HAI. In
patients who do not develop any HAIs, the total ICU stay (up to day 28) invasive device
score will be used in the regression model.
Specimen Processing and Analysis
Universal precautions were used during specimen collection, processing, and
analysis. All specimens were collected at study entry.
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Plasma Processing
Blood was collected on each participant at baseline in 5 ml ACD tubes. The
samples were placed on ice immediately and transported to the laboratory for processing
as quickly as possible. A refrigerated centrifuge was used in the hospital Core Lab to spin
the samples for 15 minutes at 2000G to separate the plasma from other blood
components. Each plasma samples was then aliquoted into 2 equal portions and stored at
-80 degrees until batch analysis. Samples were placed on dry ice when moving across
campus prior to storage in the Crowe Building freezer, where all analyses were to be
performed.
Cytokine Analysis
The cytokines for IL-6 and IL-10 were measured (pg/ml) in duplicate by Luminex
(Luminex Corporation, Austin, TX) using Human Cytokine/ Chemokine Multiplex Kits
(Millipore Corporation, Billerica, MA) according to manufactures instructions. In brief,
previously frozen plasma samples were prepared by vortexing and certifuging to remove
particulates before performing the assay. Beads were mixed according to instructions. A
standard curve was prepared with the concentrations of 3.2 pg/ml, 16 pg/ml, 80pg/ml,
400 pg/ml, 2000 pg/ml, and 10,000 pg/ml. The 96 well plate was prepared by adding 200
μl of wash buffer to each well, shaking at room temperature for 10 minutes, and then
vacuumed. Next, 25 μl of standard each curve concentration, each control, and assay
buffer were added to each well in duplicate as indicated. The plasma samples were then
added to the appropriate sample wells (25 μl) and serum matrix (25 μl) added to each
standard curve and control well. Next, 25 μl of mixed beads were added to each well. The
plate sealed and incubated overnight on the shaker at 4°C. The next day, fluid was
removed by vacuum and the plate was washed twice with 200 μl of wash buffer and
vacuumed. Next, 25 μl of detection antibodies were added and the plate was placed on
the shaker for one hour at room temperature. Next, 25 μl of Streptavidin-Phycoerythrin
was added to each well. The plate was sealed and placed on the shaker at room
temperature for 30 minutes. The plate was then vacummed and washed twice with 200 μl
of wash buffer. The beads were then resuspended in 150 μl of sheath fluid and analyzed
on the Luminex machine.
Luminex software provides an automated data interpretation report with standard
curves. It provide several report, including a bead count report, median florescent
intensity (MIF), results, and average results for duplicates. Luminex software calculates
the results by extrapolating MIF values on the standard curve. No reading can be
accurately measured if below the lowest point on the standard curve (3.2 pg/ml) or above
the highest point on the curve (10,000 pg/ml). When results occur outside of these
detectable limits, the lowest or highest detectable value is substituted for statistical
purposes. Results for each well were reviewed. According to the manufacturer
instruction, data resulting from a cell with a bead count of at least 50 beads provides
reliable results. In cases where the bead count was less than 50 or when the duplicate
results were greater than 10 percent difference, the assay was repeated to increase the
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accuracy of the measurement. A total of four were batches run. Batch one (samples 1
- 39), batch two (samples 1 - 39), batch three samples 40 - 78), and batch four (repeat
samples from batches two and three).
It was initially anticipated that only two kits would be needed to complete these
measurements and two kits were ordered. There were multiple issues with batch one due
to wells not vacumming and low bead counts. It was considered a test batch and none of
the results were used. Two additional kits were ordered to assure that the same lot
number was used, and the prior additional kit was retained to run repeat samples as
needed. Batch 4 included duplicate samples from batch two and three that were needed to
clarify the results as well as several additional duplicate samples to test reproducibility.
Before the analysis was complete, the bead counts became extremely low and it was
assumed that the Luminex needle was clogged. The system was flushed to assure that the
needle was working properly. The plate was vacuumed and beads were resuspended with
150 μl of sheath fluid, and the analysis for batch four was repeated. This time the bead
counts for the first few wells (which previously had sufficient bead counts) were
extremely low and the batch was discontinued. Limited results from batch four were
available. Results and bead counts were carefully reviewed. A total of five cytokines
were actually tested but only two are included in this dissertation study. It was a puzzling
finding that some wells (from batches 2 and 3) which had sufficient bead counts for one
cytokine but not another could have different results when retested. Each batch contained
its own standard curve and controls. Perhaps this could be explained by the fact that the
kit used for batch four had a different lot number and samples 1 - 39 had undergone one
freeze thaw cycle. Most samples were measured in duplicate and averaged. Due to the
inconsistent results of batch four, results from batch 2 and 3 were used primarily. A small
number of values are based on single and not duplicate values.
Reliability and Validity of Cytokine Measures
The literature describes a high degree of variability among earlier generation
cytokine results obtained from different manufacturers. Studies from the early 1990’s
found great variably in cytokine measurements depending on the type of fluid being
analyzed and the assay used.113 Fahey et al. compared laboratories testing for cytokines
and found both intra and inter laboratory variability. Several problems were identified
before uniform results were obtained.114 The World Health Organization established
cytokine standards to facilitate development of cytokine kits in research, and resulted in a
dramatic reduction of the variation.115 It is recommended that when measuring cytokines,
the same manufacturer’s kit, methods, and lot number are used to enhance the internal
validity of the study. Millipore reports precision percentage for inter-assay is 3.7 - 17.2
and intra-assay is 4.6 - 13.8.
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Buccal Swab Collection for DNA
The Catch-All™ Sample Collection Swabs from EPICENTRE Biotechnologies
were used to collect buccal/cheek swabs. Specimens were collected by swabbing the
inner aspect of the cheek and retaining the sample until ready for DNA extraction. All
specimens were collected without the presence of tea or coffee for at least one hour.
Yield is directly correlated with the starting amount of buccal cells; therefore, swabs were
collected in duplicate due to the concern of low yield among patients receiving
mechanical ventilation in which access to the mouth is obscured by a large bite block.
Specimens were allowed to dry at room temperature, returned to the collection sleeve,
temporarily stored at room temperature, and then transferring to a -20 degree freezer in
the Crowe building. The protocol allows for storage at room temperature for up to one
week. Several specimens were stored in a locked cabinet for 24 to 48 hours prior to
freezing.
DNA Extraction
The BuccalAmp™ Rapid DNA Extraction Kit was used to extract DNA
according to the manufactures instructions and to prepare DNA for PCR amplification
assays. In brief, frozen buccal swabs were allowed to thaw at room temperature. Tubes
containing Quick DNA Extraction Solution (stored at -20 degrees) was allowed to thaw
at room temperature. One of these tubes was then labeled for each patient. The tip of each
buccal swab was gently rotated 10 times in a tube containing Quick DNA Extraction
Solution. The swab was carefully removed while rotating and pressing on the side of the
tube to prevent solution loss. The top was secured tightly on each tube, and then the
tubes were vortexed for 10 seconds, incubated at 65°C for 1 minute, vortexed for 15
seconds, incubated at 98°C for 2 minutes, and then vortexed for 15 seconds. This process
was done in batches as samples accumulated. A random sample (n = 6) was tested by
spectrophotometry to assure the presence of DNA by examining 260/280 ratios, and then
samples were stored at -70 degrees until ready for genetic testing. In the random sample
5/6 samples contained DNA. All samples were taken to the MRC to test the DNA
quantity by NanoDrop but after checking several samples it was discovered that the
proprietary reagents in the rapid extraction kits interfered with these results. According to
manufactures instructions, SNP analysis can be performed without quantization or
purification using this method.
DNA Analysis
SNP analysis was performed by real-time polymerase chain reaction (PCR) using
the LightCycler® 480 Instrument, located in UTHSC’s Molecular Resource Center
(MRC). TaqMan® SNP Genotyping Assays, Human, SM (40X) for rs1800795 and
rs1800896 from Applied Biosystems (Life Technologies, United States, 2006) contained
florescent reporter tags (VIC and FAM) to determine alleles 1 and 2, respectively. Table
3-2 includes SNP primer details. A context sequence is given for proprietary primers.
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Table 3-2. SNP Primer and Reporter Details for Genotyping.
Cytokine
RS number

IL-6
rs1800795

Forward Primer

CGACCTAAGCTGCACTTTTCC

Reverse Primer

GGGCTGATTGGAAACCTTATT
AAGATTG

IL-10
rs1800896
.
.

VIC Reporter
Sequence

CCTTTAGCAT[G]GCAAGAC

.

FAM Reporter
Sequence

CCTTTAGCAT[C]GCAAGAC

.

.

TCCTCTTACCTATCCCT
ACTTCCCC[T/C]TCCCA
AAGAAGCCTTAGTAGT
GTTG

Context
Sequence

VIC Reporter

Targets C

Targets A

FAM Reporter

Targets G

Targets G

X Allele

GG

GG

Y Allele

CC

AA

Both Alleles

GC

AG

* Roche LightCycler®480 Software reports describe alleles as Allele X, Allele Y, or
Both Alleles. Allele X binds to fluorescent probes FAM at 483-533 nm, Allele Y binds
to fluorescent probes VIC/HEX/Yellow555 at 523-568 nm.
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Roche LightCycler® 480 Probe Master Mix and PCR plates were obtained from the
MRC. A Master Mix was specifically made for each analysis which contained the
Genotype Assay, Probe Master Mix, and PCR-grade water. The Genoype Assay was
adjusted to a 20x concentration in the Master Mix. The total volume of each Master Mix
depended on the number of reactions. The final reactions volume was 10 μl and
contained 1 μl of unpurified DNA, 0.25 μl of the Genotype Assay, 5.0 μl TaqMan Master
Mix, and 3.75 μl PCR-grade water. Real-time PCR was performed according to
manufacturer’s instructions. Standard PCR methods were used. A negative control using
PCR-grade water rather than DNA was included in each experiment. PCR included one
preincubation period (1 cycle at 95°C), incubation (45 cycles at 95°C, 62°, and 72°C),
and cooling period (1 cycle at 40°C). The primer target temperature is typically set
approximately 5°C below the primer melting temperature (Tm); however, the Applied
Biosystem’s TaqMan® SNP Genotyping Assays are all optimized for 60°C. If additional
optimization is required, the manufacturer recommends either shortening cycle time to 40
or increasing the temperature to 62°C.
Statistical Analysis
Data were analyzed with SAS (Version 9.1) using standard statistical techniques,
including chi-square, student’s t-test, correlations, and Cox regression modeling.
Univariate testing was performed on all continuous variables, and variables not normally
distributed were either log transformed to achieve a normal distribution or nonparametric tests were performed. Chi-square tests with expected cell counts less than five
were analyzed using Fisher’s Exact test. An alpha level of 0.05 was considered
statistically significant. Each aim includes pre-specified research questions and assumes
complete data for the primary variables of interest.
Aim 1
This aim investigates whether baseline protein expression levels of proinflammatory cytokines, anti-inflammatory cytokines, or their ratios influence the
development of subsequent HAI in patients with sepsis.
Chi-square (χ2) tests were performed to test the proportions of patients with and
without high systemic inflammation (4th quartile, IL-6 vs. other quartiles) who develop
one or more HAI. χ2 tests were performed to test the proportions of patients with and
without high systemic inflammation (4th quartile, IL-10 vs. other quartiles) who develop
one or more HAI. The ratio of IL-6:IL-10 were calculated and each participant
categorized based on their ratio. A ratio greater than 1 indicates a more prominent proinflammatory response, a ratio less than one indicates a more prominent antiinflammatory response. Student’s t was performed to determine prominent inflammatory
response among those who do and do not develop one or more HAI. Mean cytokine

34

levels (IL-6, IL-10) and their ratio (IL-6:IL-10) will be compared using student’s t among
participants who do and do not develop a HAI during their ICU stay.
1.1
1.2
1.3
1.4

Does an exaggerated pro-inflammatory response influence subsequent
HAI development in patients with sepsis?
Does an exaggerated anti-inflammatory response influence subsequent
HAI development in patients with sepsis?
Do the ratios of pro-inflammatory and anti-inflammatory cytokines
influence subsequent HAI development in patients with sepsis?
Describe baseline cytokine patterns among patients with sepsis who do
and do not develop subsequent HAI?
Aim 2

This aim investigates the variance in cytokine genes to determine if they
influence levels of protein expression or development of HAI.
ANOVAs were performed to determine the cytokine levels for each genotype.
Chi-square analysis were also used to compare differences in common polymorphisms
among those with exaggerated inflammation (4th quartile) at baseline as well as among
those who do and do not develop HAIs.
2.1
2.2
2.3
2.4
2.5

Is a particular IL-6 genotype associated with a higher level of IL-6?
Is a particular IL-10 genotype associated with higher levels of IL-10?
Is a particular IL-6 genotype associated with a higher rate of HAI
development?
Is a particular IL-10 genotype associated with a higher rate of HAI
development?
Is a particular haplotype associated with a higher rate of HAI
development?
Aim 3

This aim investigates the effects of protein expression levels, genetic variation,
and environment on development of HAI.
A series of Cox regression analyses was performed among those who did and did
not develop HAIs during ICU stay (or up to 28 days in those with a prolonged ICU stay)
controlling for a number of potentially confounding variables including age, race, sex,
severity of illness (APACHE II), baseline cytokines, ICU length of stay, invasive device
score, steroid use, and potential confounders. Questions 3.1-3.7 were answered by
univariate testing. Questions 3.8 and 3.9 were answered by multivariate testing.
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3.1.
3.2.
3.3.
3.4.
3.5.
3.6.
3.7.
3.8.
3.9.

What is the risk ratio to predict development of HAI for each 10 point
increase in APACHE II?
What is the risk ratio to predict development of HAI for each additional
invasive devise?
What is the risks ratio to predict development of HAI given IL-6 -174G
genotype?
What is the risks ratio to predict development of HAI given IL-10 -1082G
genotype?
What is the risk ratio to predict development of HAI for each 10 point
increase in pro-inflammatory cytokine?
What is the risk ratio to predict development of HAI for each 10 point
increase in anti-inflammatory cytokine?
What is the risk ratio to predict development of HAI for each 10 point
increase in ratio of pro- to anti-inflammatory cytokine?
Which variables are the strongest predictors of HAI development?
What is the final regression model for HAI?
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CHAPTER 4. RESULTS
Study results are presented in this chapter. We begin with a description of study
recruitment and baseline demographics including details surrounding the initial sepsis or
suspected sepsis event. Next, we provide a detailed description among subjects
developing HAI in this study. We then discuss several ICU outcome variables based on
development of HAI and based on exaggerated or not exaggerated pro- or antiinflammatory response. Lastly, results are described by each specific aim.
Recruitment
Screening occurred over an 18 month period from February 2009 until July 2010.
Recruitment details are shown in Figures 4-1 and 4-2. A total of 539 subjects were
screened with 215 (39.9%) meeting inclusion criteria. Among all patients meeting
inclusion criteria, 105 (48.8%) met study related exclusion criteria, 32 (14.9%) had other
reasons for exclusion, and 78 (36.3%) were enrolled. Approximately seven patients were
screened for each patient enrolled. Some of the other reasons for exclusion included
improvement and early transfer out of ICU, death, prior study subjects, or out of the
window when evaluated.
Demographics and Baseline Infections
Subject demographics and clinical characteristics are shown in Table 4-1. The
study population consisted of older (65.5 ± 12.6) male (97.9%) veterans who were
admitted to the ICU primarily from the emergency room (48.7%) or general medical
ward (30.8%) with sepsis as a primary or underlying condition. This population included
a high percentage with co-morbidities (93.6%) with less than half (43.6%) having
diabetes. This population had a high severity of illness given their high APACHE II (20.6
± 6.4) and organ failure scores. Fifty (64.1%) subjects had at least two organ failures at
baseline.
Characteristics of baseline infection findings at ICU admission are shown in
Table 4-2 and a rank percentage of baseline organisms identified is shown in Table 4-3.
Among all baseline cultures, Staphylococcus Coagulase Negative was the most common
microorganism, followed by Pseudomonas aeruginosa and Escherica coli. The most
common type of infections among the 99 baseline infections were pneumonia (35.4%
CAP or HACP) and urinary tract infection (31.3%). All patients had been placed on
empiric antibiotics for their definitive or suspected infections at baseline. No microorganisms were identified in 22 (28.2%) subjects. There were similar numbers of subjects
with gram positive and gram negative infections. Blood-stream infection accompanied
32.0% of identified infections, with no source identified in 2 (3.4%) subjects with a blood
stream infection. Hypothermia or hyperthermia was present in 58 subjects. Baseline
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539 Screened

318 Did Not
Meet Inclusion

215 Met Inclusion
105 Study Specific Exclusion:
• 36 Immunosuppressants
• 28 Immunosuppressed
• 5 Child-Pugh Class C
• 35 No consent
32 Other Exclusions
• 1 Expired
• 2 Improved
• 8 Out of Window
• 3 Prior subjects
• 8 Transferred before Enrolled
• 10 Unclear

78 Enrolled

Figure 4-1. Subject Recruitment.

38

Monthly Recruitment
12

10

10
7

8
6
3

4
2

3

3

6

6

6

6

4

3

6

4

1

1

5

4

0

0

July

June

May

April

March

February

January

December

November

October

September

August

July

June

May

April

March

February

Figure 4-2. Monthly Subject Recruitment.
Legend: Down facing arrows denote protocols changes. The first arrow represents a
protocol clarification of SIRS criteria by adding > 10% bands. The second arrow
represents a protocol change to allow recruitment of MICU patients located in the SICU
unit.
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Table 4-1. Demographic and Clinical Characteristics.
All Subjects
(n=78)
65.5 ± 12.6

Variables
Age (years)
Sex
Male
Female
Race
Black
White
BMI*
Admitted From
Emergency Room
Another ICU
Operating Room
Spinal Cord Unit
Ward
Hospital Days Prior to ICU Admission†
Prior Hospitalization for More than 1 Week
Primary Reason for ICU Admission
Sepsis or Severe Sepsis
Septic Shock
Respiratory Distress or Failure
Other ‡
Charlson Comorbidity Index > 0 §
Diabetes
Current Smoker
Steroids Less than 1 mg/kg ‖
APACHE II
Sequential Organ Failure Score
Multiple Organ Dysfunction Score
Two or More Organ Failures

74 (94.9)
4 (5.1)
30 (38.5)
48 (61.5)
24.6 (10.1)
38 (48.7)
3 (3.8)
4 (5.1)
9 (11.5)
24 (30.8)
1 (3)
13 (16.7)
33 (42.3)
20 (25.6)
13 (16.7)
12 (15.4)
73 (93.6)
34 (43.6)
21 (26.9)
17 (21.8)
20.6 ± 6.4
6.9 ± 3.9
1.9 ± 1.2
50 (64.1)

Note: Data are reported as mean ± standard deviation, median (interquartile range), or
count (percentage).
* BMI denotes body mass index. BMI range 11.0 - 72.6.
† Hospital days prior to ICU admission are reported as median (IQR), range 0 - 260.
There were 22 (28.2%) patients who were in the hospital greater than 3 days and 4 (5.1%)
who were hospitalized for more than 28 days.
‡ Other reasons for ICU admission include: 3 post code, 2 non ST elevation myocardial
infarctions, 2 gastro-intestinal bleeding, 1 congestive heart failure, 1 diabetic
ketoacidosis, 3 post-op (carotid endarterectomy, knee replacement, gastric-tube
placement with peritonitis).
§ The Charlson Comorbitidy Index includes 19 medical conditions with weighted scores
ranging from 1 to 6 for each condition and a total possible score of 0 - 37.116
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Table 4-1. Continued.
‖ Two subjects transferred from the ward had no prior steroids given on the ward or
recorded in BCMA, but it was discovered upon later chart review that they received 1
dose of steroids > 1 mg/kg in the ER. These subjects have been retained in all analysis
following an intention to treat principle.
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Table 4-2. Baseline Infection Findings at ICU Admission.
Variables
Definitive Infections
Type of Infection*
Primary Bacteremia
Aspiration Pneumonia
Community Acquired Pneumonia
Health Care Associated Pneumonia
Gastrointestinal or Intra-abdominal Infection
Urinary Tract Infection
Skin and Soft Tissue Infection
Bone and Joint Infection
CNS Infection
Cardiovascular System Infection
Malaria
Number of Patients with 2 Sites of Infection
Accompanying Bacteremia
Type of Organism
Gram Positive
Gram Negative
Mixed Gram Positive and Gram Negative
Fungal
Mixed Fungal and Gram Positive
Mixed Fungal and Gram Negative
Mixed Fungal, Gram Positive, and Gram Negative
No Organism Identified
Hyperthermia (Temperature > 100.4)
Hypothermia (Temperature < 96.8)
SIRS
Temperature (°F) †
Respiratory Rate
White Blood Cell Count (Thousands)
Bands ‡
Heart Rate Minimum
Minimum SBP
Number of Fluid Boluses Required §
Use of Vasopressors Required
PaO2:FiO2 Ratio
C-reactive Protein
Lactate
Hours to ICU admission
Timing to First Antibiotics
Surgical Treatment
Other Treatment
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All Subjects
(n = 78)
51 (65.4)
2
1
15
20
10
31
12
2
2
3
1
21 (26.9)
25 (32.0)
19 (24.3)
18 (23.1)
8 (10.2)
4 (5.1)
3 (3.4)
3 (3.4)
1 (1.3)
22 (28.2)
23 (29.5)
35 (44.9)
3.1 ± 0.7
98.5 ± 3.0
30.9 ± 8.6
18.7 ± 15.5
22.2 ± 16.3
92.0 ±19.4
85.6 (23.3)
3.3 ± 3.3
25 (32.0)
210 ± 140
206.7 ± 156.7
3.2 ± 2.7
4.6 (6.0)
1.5 (3.75)
11 (14.1)
10 (12.8)

Table 4-2. Continued.
All Subjects
(n = 78)
26 (33.3)
8 (10.3)

Variables
Conventional Mechanical Ventilation
Noninvasive Positive Pressure Ventilation

Note: Data are reported as mean ± standard deviation, median (interquartile range), or
count (percentage). The number of subjects is less than 78 for the following variables: Creactive protein (n = 65), lactate (n = 64), timing to ICU admission (n = 72), timing to
first antibiotics (n = 71).
* Type of infection includes all infections. There were a total of 99 suspected or
definitive infections in 78 patients. The total number of infections in each category is
shown. Gastrointestinal or intrabdominal infections include four with C-difficile colitis,
five with peritonitis, and one with cholecystitis. Cardiovascular system infections include
two with catheter related infection and one with endocarditis. Bone and joint infections
include one with osteomylitis and one with septic arthritis. CNS infection includes one
with encephalitis and one with meningitis. Urinary tract infection includes one case of
toxic shock syndrome post urology procedure detecting an abscess.
† Temperature range from 93.5 to 104.3°F.
‡ Manual differential counts were only done in 51 subjects.
§ Fluid bolus range from 0 - 14 liters.
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Table 4-3. Most Common Baseline Micro-organisms.
Organism
Staphylococcus coagulase negative (G+cocci)
Pseudomonas aerugnosa (G-rods)
E. Coli (G-rods)
Klebsiella pneumoniae (G-rods)
Candida albicans (yeast)
Staphylococcus aureus (G+cocci)
Enterococcus spp. (G+cocci)
Probable Candida - no id (yeast)
Serratia marcescens (G-rods)
Clostridium spp. (G+rods)

All Organisms Cultured
26 (10.9)
20 (8.4)
20 (8.4)
18 (7.6)
18 (7.6)
16 (6.7)
16 (6.7)
16 (6.7)
6 (2.5)
5 (2.1)

Note: The number and percentage is shown. This table is based on all cultures
completed up to day 3. Only organisms present in at least 5 cultures are shown. There
were 22 (28.2%) subjects with no baseline organism identified.
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lactate and CPR levels were elevated. Subjects received an average of 3.3 liters of fluid
resuscitation on the day of ICU admission. In general, fluids were given as a rapid bolus
in response to hypotension but precise timing of fluid resuscitation was not recorded.
The maximum volume received among participants was 14 liters in one patient, and there
were 17 patients that did not require fluid resuscitation. Additionally, 25 (32.0%)
required vasopressors and 34 (43.6%) required either conventional or non-invasive
positive pressure ventilation at baseline. Median hours until first antibiotic and ICU
admission were 1.5 and 4.6 hours, respectively.
Description of First Health Care Associated Infection
A total of 17 participants developed at least one HAI. Characteristics of the first
HAI is shown in Table 4-4 and a rank percentages of organisms identified are shown in
Table 4-5. Candida was responsible for 11 (64%) of all identified first HAIs. There were
three species of Candida identified (Candida albicans, Candida glabrata, Candida
tropicalis) in addition to others not identified. The second most frequent organism was
Staphylococcus Coagulase Negative. The primary type of infection was bloodstream
infection (47.1%) followed by pneumonia (23.5%) and urinary tract infection (17.6%).
Fever was present in approximately half (47%) who developed HAI and the
average SIRS score was 2.1 ± 0.9. Fluid bolus was required in 4 (23.5%) with the
volume ranging from 0.5 to 5 liters. Three participants (17.7%) required vasopressors to
support blood pressure, and 10 (58.8%) had moderate organ failure in 2 or more organs.
Lactate and CPR levels were elevated.
Measureable environmental factors included invasive devices, staffing ratios, and
receipt of blood products. All participants (100%) developing HAI had a central line,
88.2% had a Foley catheter, and 70.5% were receiving mechanical ventilation (median 8
days) at the time of first HAI. Three participants (17.7%) had at least one eight hour
period with a nurse-to-patient ratio of more than 2:1 within 48 hours preceding the first
HAI. Seven participants (41.2%) received blood products within 48 hours preceding the
first HAI.
Differences in Variables among Those Who Did and Did Not Develop HAI
A summary of ICU outcomes is shown in Table 4-6 for all participants
comparing those who did and did not develop HAI. There were several significant
differences between those who did and did not develop HAI. Those who developed HAI
had a higher number of invasive devices (p = 0.04) at ICU discharge as well as a higher
cummulative invasive device score (p < 0.0001). Those developeing HAI had a higher
number of organs with at least moderate dysfuction (2.4 ± 2.3 vs. 1.1 ± 1.3, p = 0.04),
required more use of vasopressors (64.7% vs. 27.9%, p=0.009) with more episodes of
new shock (p = 0.003). Those developing HAI had an average ICU length of stay more

45

Table 4-4. Description of First Health Care Associated Infection.
Variables
Day of ICU
Type of Infection
Bloodstream Infection
Pneumonia
Urinary Tract Infection
Gastrointestinal System Infection
Cardiovascular System Infection-VASC
Polymicrobial Infection
Resistant Organism
Fever or Hypothermia Present
SIRS
Temperature
WBC
Respiratory Rate
Heart Rate Minimum
Minimum SBP
Number Requiring Fluid Bolus
Use of Vasopressors Required
PaO2:FiO2 ratio
Sequential Organ Failure Assessment
Multiple Organ Dysfunction Score
C-reactive Protein
Lactate
CPIS Score
Change in Antibiotics
Receiving Mechanical Ventilation
Duration of MV at Time of HAI*
Cumulative Invasive Devise Score at Time of HAI
Invasive Devices Present:
Endotracheal Tube
Tracheostomy
Central Line
Foley Catheter
Any Patient to Nurse Ratio > 2:1 in Preceding 48 Hours
Received Blood Products in Preceding 48 Hours

Developed HAI
(n = 17)
9 (5)
8 (47.1)
4 (23.5)
3 (17.6)
1 (5.9)
1 (5.9)
3 (17.7)
4 (23.5)
8 (47.0)
2.1 ± 0.9
97.9 ± 1.8
18.5 ± 9.5
30 ± 8
75 ± 15
103.7 ± 18.7
4 (23.5)
3 (17.7)
196 ± 98
6.2 ± 4.7
2.2 ± 1.6
146.2 ± 157.9
1.8 ± 1.5
3.5 ± 2.4
12 (70.6)
12 (70.6)
8 (7)
52.8 ± 26.7
10 (58.8)
2 (11.7)
17 (100%)
15 (88.2)
3 (17.7)
7 (41.2)

Note: Data are reported as mean ± standard deviation, median (interquartile range),
or count (percentage).
* Two patients had prior mechanical ventilation during this ICU stay but were off
for more than 48 hours at the time of their HAI. One had received three days of MV
and off five days when HAI developed; the other had been on MV five days, and off
six days when HAI developed.
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Table 4-5. First HAI Micro-organisms (Ranked).
Organisms
Candida albicans*
Staphylococcus coagulate negative †
Candida glabrata ‡
Candida tropicalis ‡
Candida spp not identified §
Acinetobacter baumanni ‖
Clostridium difficile
Escherica coli ¶
Klebsiella pneumoniae ¶
Pseudomonas aeruginosa #

Rank and Percentage
5 (25)
4 (20)
2 (10)
2 (10)
2 (10)
1 (5)
1 (5)
1 (5)
1 (5)
1 (5)

Candida species involved 11 (64%) of all 17 identified first HAIs.
* 2 HCAP, 3 fungemia. One Candida albicans was mixed with Klebsiella
pneumoniae in the BAL.
† 2 blood stream infections, 1 HCAP, 1 Cardiovascular system infection –VASC.
Two Coagulate Negative Staphylococcus were mixed, one with Candida albicans in
the BAL and the other with Candida tropicalis in the blood
‡ 2 fungemia
§ 2 UTI, 1 with fungemia
‖ UTI
¶ HCAP
# VAP
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Table 4-6. Differences in Variables among Those Who Did and Did Not Develop Health Care Associated Infections.
Variables
Any HAI Develop During ICU Stay
Number of Invasive Devices at Discharge
Total Invasive Device Score at Discharge
SOFA Score at Discharge
MODS Score at Discharge
SIRS Score
Mechanical Ventilation Duration (n = 34)
Use of Vasopressors during ICU Stay
Duration of Vasopressor Use (Days)
Any New Shock during ICU Stay
Blood Products during ICU Stay
ICU Survival
Discharge Destination
Remained in ICU
Ward
Spinal Cord Unit
Morgue
Duration of ICU stay
Readmissions to ICU within 28 Days
Any Nurse Patient Ratio Greater than 2:1
Steroids Use during ICU Stay
Insulin Use during ICU Stay
Received Blood Products during ICU Stay

All subjects
(n = 78)
17 (21.8)
3.3 ± 1.3
35.6 ± 35.7
4.6 ± 4.7
1.4 ± 1.6
1.8 ± 0.9
8.0 ± 6.5
28 (35.9)
3.9 ± 3.0
9 (11.5)
44 (56.4)
64 (82.1)
.
1 (1.3)
56 (71.8)
7 (9.0)
14 (18.0)
8.0 ± 6.2
12 (15.4)
14 (18.0)
40 (51.3)
57 (73.1)
44 ( 56.4)

No HAI
(n = 61)
0 (0.0)
3.1 ± 1.3
23.9 ± 23.0
4.1 ± 4.2
1.1 ± 1.3
1.9 ± 1.0
5.9 ± 4.7
17 (27.9)
3.9 ± 3.1
3 (4.9)
31 (50.8)
52 (85.3)
.
0 (0.0)
46 (75.4)
6 (9.8)
9 (14.8)
6.4 ± 4.0
8 (13.1)
11 (18.0)
26 (42.6)
42 (68.9)
31 (50.8)

Developed HAI
(n = 17)
17 (100)
3.8 ± 1.3
77.7 ± 41.8
6.6 ± 5.8
2.4 ± 2.3
1.7 ± 0.8
11.1 ± 7.6
11 (64.7)
4.1 ± 3.2
6 (35.3)
13 (76.5)
12 (70.6)
.
1 (5.9)
10 (58.8)
1 (1.5)
5 (29.4)
15.3 ± 7.1
4 (23.5)
3 (17.7)
14 (82.4)
15 (88.2)
13 (76.50

Note: Data are reported as mean ± standard deviation, median (interquartile range), or count (percentage).
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P
Value
.
0.04
< 0.0001
0.10
0.04
0.35
0.03
0.009
0.87
0.003
0.10
0.17
0.14
.
.
.
.
< 0.0001
0.06
1.00
0.005
0.13
0.09

than twice compared to those not developing HAI, and required a longer duration of
mechanical ventilation. There was a higher rate of steroid use in those developing HAI
compared to those who did not (82.4% vs. 42.6%, p = 0.005). Patients developing HAI
also had a trend (p = 0.06) towards higher ICU readmissions rate within 28 days as
compared to those who did not develop HAI.
Differences in Variables by Pro- and Anti-inflammatory Cytokine Quartiles among
Those Who Did and Did Not Develop HAI
A summary is provided in Table 4-7 comparing participants with high baseline
systemic inflammation (fourth quartile) to participants without high baseline systemic
inflammation (first-third quartiles) for both the pro-inflammatory cytokine IL-6 and the
anti-inflammatory cytokine IL-10. Steroid use was the only significant difference among
participants with a high anti-inflammatory response versus those without (84.2% vs.
40.7%, p = 0.0013). Among those with a high pro-inflammatory response there were
several significant differences in comparison to those with a lower pro-inflammatory
response. Organ dysfunction was higher, and there was a three fold higher number of
participants requiring vasopressors (73.7% vs. 23.7%, p < 0.0001).There was also a
higher percentage of steroid use (73.7% vs. 44.1%, p = 0.03), as well as participants with
arrythmias (52.6% vs. 18.6%, p = 0.007). ICU Survival was similar for all participants
regardless of baseline pro- or anti-inflammatory cytokine level.
Cytokine and Genotype Measurements
Cytokines were measured by Luminex in batches. Details are described in the
methods section. The detection limits for each cytokine was 3.2 pg/ml and 10,000 pg/ml.
A total of 5 (6.4%) of IL-6 levels and 29 (37.2%) of IL-10 levels were below the
detection limit. In these cases, a surrogate of 3.2 pg/ml was used for statistical purposes.
DNA isolation occurred in batches during recruitment and after recruitment was
complete. Genotyping was perfomed after study recruitment was complete using End
Point Genotyping by Real-Time PCR. The LightCycler® 480 software (version LCS480
1.5.0.39) by Roche (Mannheim, Germany) provided automated genotyping calls for each
participant. A call of either Allele X, Allele Y, Both Alleles, Unknown, or Negative was
provided for each of the 96 wells. Gentotypes for Allele X, Allele Y, and Both Alleles
were described in Table 3.2. A negative call was received for the negative controls,
empty wells, and for other possible reasons such as sample quality, inhibition, or
primer/dimer formation. Unknown calls were received when the software was unable to
determine the genotype.
A test run was performed to optimize the PRC reaction which included the first 10
participant’s samples under conditions described in the methods section. Replication was
not observed until 30 cycles during the test run; therefore, the cycle time was increased to
50 from 45 cycles based on expert guidance from a MRC scientists who assisted with
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Table 4-7. Differences in Variables Pro- and Anti-inflammatory Cytokine Quartiles.

Variables
Number of Subjects
Any HAI Develop During ICU Stay
Invasive Device Score at Discharge
Invasive Devices at Discharge
SOFA Score at Discharge
MODS Score at Discharge
SIRS Score
Mechanical Ventilation Duration*
Use of Vasopressors during ICU stay
Any New Shock during ICU stay
Blood Products during ICU stay
ICU Survival
Discharge Destination
Remained in ICU
Ward
Spinal Cord Unit
Morgue
Duration of ICU stay
Readmissions to ICU within 28 days
Any Nurse Patient Ratio > 2:1
Steroids Use during ICU stay
Insulin Use during ICU stay
Arrhythmias
Cardiac Arrest

Pro-inflammatory Cytokine: IL-6
1st-3rd
4th
P
Quartiles
Quartile
Value
59
19
11(18.6)
6 (31.6)
0.55
31.9 ± 33.5 47.0 ± 40.1
0.15
3.2 ± 1.2
3.5 ± 1.7
0.45
3.7 ± 3.6
7.5 ± 6.4
0.02
1.1 ± 1.3
2.2 ± 2.1
0.04
1.8 ± 0.9
2.0 ± 0.9
0.50
7.1 ± 5.6
10.1 ± 8.3
0.32
14 (23.7)
14 (73.7)
<0.0001
6 (10.2)
3 (15.8)
0.68
32 (54.2)
14 (73.7)
0.60
50 (84.8)
14 (73.7)
0.31
.
.
0.22
0 (0.0)
1 (5.3)
.
44 (74.6)
12 (32.2)
.
6 (10.2)
1 (5.3)
.
9 (15.3)
5 (26.3)
.
7.4 ± 5.6
10.1 ± 7.4
0.16
9 (15.3)
3 (15.9)
0.26
13 (22.0)
1 (5.3)
0.16
26 (44.1)
14 (73.7)
0.03
43 (72.9)
14 (73.7)
0.95
11 (18.6)
10 (52.6)
0.007
13 (22.0)
7 (36.8)
0.23

Anti-inflammatory Cytokine: IL-10
1st-3rd
4th
P
Quartiles
Quartile
Value
59
19
12 (20.3)
5 (26.3)
0.43
32.4 ± 34.3 45.6 ± 39.1
0.19
3.3 ± 1.3
3.4 ± 1.6
0.77
4.2 ± 4.3
6.1 ± 5.6
0.19
1.2 ± 1.6
1.8 ± 1.8
0.23
1.9 ± 1.0
1.7 ± 0.9
0.66
7.1 ± 5.6
10.2 ± 8.9
0.29
18 (30.5)
10 (52.6)
0.08
7 (11.9)
2 (10.5)
1.00
33 (55.9)
11 (57.9)
0.88
49 (83.1)
15 (79.0)
0.74
.
.
0.37
0 (0.0)
1 (5.3)
.
44 (74.6)
12 (63.2)
.
5 (8.5)
2 (10.6)
.
10 (17.0)
4 (21.1)
.
7.5 ± 5.7
9.7 ± 7.2
0.24
8 (13.6)
4 (21.1)
0.40
13 (22.0)
1 (5.3)
0.16
24 (40.7)
16 (84.2)
0.0013
46 (78.0)
11 (57.9)
0.09
14 (23.7)
7 (36.8)
0.26
15 (25.4)
5 (26.3)
0.94

* Duration of mechanical ventilation includes data for 34 subjects who received mechanical ventilation, n=24 versus 10,
respectively.
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LightCycler initial set-up and with calculations required for initial reaction volumes. The
genotype results for IL-6 under these conditions included 32 Negatives and 5 Unknowns.
Applied Biosystems technical support advised that although replication did not begin
until 30 cycles, it is more appropriate for end point genotyping not to increase cycle time
beyond 45 cycles. All samples were re-tested for IL-6 genotyping using the original test
conditions (45 cycles) and resulted in only 2 undetermined genotypes (1 negative and 1
unknown call). These 2 missing genotypes were available from the initial test run.
Genotyping for IL-10 was performed as described in the methods section. The
initial undetermined calls were 30 unknown and 1 negative. The reaction was optimized
by increasing the temperature to 62°C, reducing the number of unknowns to 7. Manual
calls were required for these 7 subjects: 2, 22, 27, 31, 50, 58, and 69. These subjects were
manually called heterozygotes based upon visual clustering and endpoint fluorescence
values. All unknown calls had a confidence score less than 0.50 and endpoint
fluorescence values were not significantly higher than each other. Although the software
algorithm is proprietary, genotypes that were automatically called included an endpoint
fluorescence of at least one or more fold higher than the lower endpoint fluorescence
value. The endpoint fluorescence value for those called as heterozygous contained
differences but they were generally much less than a fold difference.
Genotype Allele Frequencies
The allele frequencies are shown for rs1800795 and rs1800896 genotypes in
Table 4-8 and 4-9, respectively. These tables also show allele frequencies for all subjects
as well as white and black sepsis patients who do and do not develop HAI. Note that
there were no significant differences between the percentage of blacks and white sepsis
patients who do and do not develop HAI (23.3% vs. 20.8%, p = 0.79).
For rs1800795, there were no significant allele frequency differences among those
who do and do not develop HAI (p = 0.59); however, when examining racial differences
in genotype and controlling for those who do and do not develop HAI differences were
noted. There was a significant difference in rs1800795 genotype among black patients
with sepsis who did not develop HIA compared to whites patients with sepsis who did
not develop HAI (p = 0.0056). Specifically, black patients had a lower CG (17.4% vs.
42.1%) and higher GG (82.6% vs. 42.1%) than white patients. There were no racial
differences when comparing white and black sepsis patients who developed HAI (p
= 1.0).
For rs1800896, there were no significant allele frequency differences among those
who do and do not develop HAI (p = 0.16). There were no significant racial differences
among those who did (p = 1.0) and did not develop HAI (p = 0.41).
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Table 4-8. RS1800795 Genotype and Allele Frequencies.
Population
All
White
HAI
No HAI
Black
HAI
No HAI

Number
78
48
10
38
30
7
23

CC
0.090
0.146
0.100
0.158
0.000
0.000
0.000
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CG
0.359
0.437
0.500
0.421
0.233
0.429
0.017

GG
0.551
0.417
0.400
0.421
0.767
0.571
0.826

Table 4-9. RS1900896 Genotype and Allele Frequencies.
Population
All
White
HAI
No HAI
Black
HAI
No HAI

Number
78
48
10
38
30
7
23

AA
0.218
0.271
0.100
0.316
0.133
0.000
0.174
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AG
0.488
0.437
0.500
0.421
0.567
0.571
0.565

GG
0.295
0.292
0.400
0.263
0.300
0.429
0.261

Genotype Comparisons to HapMap 3 Reference Population
There were differences in the genotype of sepsis patients as compared to a normal
HapMap3 reference population (see Table 4-10). White (and not black) patients with
sepsis had a significantly different (p = 0.02) IL-6 genotype with higher GG (41.7%
versus 24.8%) and lower CC (14.6% versus 31.9%) genotypes when compared to a
normal reference. When examining IL-10 genotypes, black (and not white) patients with
sepsis had a significantly higher GG (30.0% versus 12.2%) and lower AA (13.3% versus
44.9%) genotype when compared to a normal reference.
Baseline Cytokine Levels by Genotype and Haplotypes
Plasma cytokine levels were right skewed and required log transformation for
statistcs requiring a normal disturbution. Table 4-11 provides a summary of plasma IL-6
and IL-10 levels. Median IL-6 levels were higher than median IL-10 levels. Table 4-12
provides cytokine levels and their ratio for each genotype. Median IL-6 levels were
highest among participants with the CC IL-6 genotype and also among participants with
the GG IL-10 genotype. Median IL-10 levels were highest among participants with the
AA IL-10 genotype and also among participants with the CG IL-6 genotype. Figures 4-3,
4-4, 4-5 and 4-6 provide box-plots of pro- and anti-inflammatory cytokines and their
ratios by for IL-6 and IL-10 genotypes. Each figure contains two images. The top image
shows the skewed data distribution prior to log transformation, and the lower image
shows the log transformed data distribution.
Aim 1
The primary goal of aim one was to investigate whether baseline protein
expression levels of pro-inflammatory cytokines, anti-inflammatory cytokines, or their
ratios influence the development of subsequent HAI in patients with sepsis.
There was no significant difference in levels of pro-inflammatory cytokine, antiinflammatory cytokine, or their ratio among subjects who did and did not develop at least
one HAI during their ICU stay. This aim was explored by comparing lower quartiles to
the higher fourth quartile for proinflammatory cytokine IL-6 and anti-inflammatory
cytokine IL-10, as well as comparing their ratios. Patients in the fourth quartile were
considered to have an exaggerated inflammatory response as compared to those in other
quartiles. Specifically, an exaggerated pro-inflammatory response was present in 6
(31.6%) compared to 11 (18.6%) participants without an exaggerated pro-inflammatory
response who developed subsequent HAI. This difference was not significant (p = 0.55).
Likewise, an exaggerated anti-inflammatory response was present in 5 (26.3%) compared
to 12 (20.3) participants without an exaggerated anti-inflammatory response who
developed subsequent HAI. This difference was also not significant (p = 0.43). There
was also no significant difference in the log of proinflammatory to anti-inflammatory
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Table 4-10. Genotype Comparisons of IL-6 and IL-10 SNPs among Sepsis and HapMap Reference Population.

Genotype
IL-6
CC
CG
GG

HapMap
(n = 324)
.
72 (22.2)
116 (35.8)
136 (42.0)

Sepsis
(n = 78)
.
7 (9.0)
28 (35.9)
43 (55.1)

P
Value
0.01
.
.
.

HapMap:
Black
(n = 98)
.
0 (0)
18 (18.4)
80 (81.6)

IL-10
AA
AG
GG

.
92 (28.4)
158 (48.8)
74 (22.8)

.
17 (21.8)
38 (48.7)
23 (29.5)

0.35
.
.
.

.
44 (44.9)
42 (42.9)
12 (12.2)

Sepsis
Black
(n = 30)
.
0 (0)
7 (23.3)
23 (76.7)
.
4 (13.3)
17 (56.7)
9 (30.0)

P
Value
0.60
.
.
.

HapMap
White
(n = 226)
.
72 (31.9)
98 (43.4)
56 (24.8)

Sepsis
White
(n = 48)
.
7 (14.6)
21 (43.8)
20 (41.7)

P
Value
0.02
.
.
.

0.002
.
.
.

.
48 (21.2)
116 (51.3)
62 (27.4)

.
13 (27.1)
21 (43.8)
14 (29.2)

0.54
.
.
.

Note: The reference population is the HapMap 3. The HapMap 3 sample included in this comparison includes normal
individuals from African ancestry in Southwest USA (black) and Utah residents with Northern and Western European
ancestry (white).109
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Table 4-11. Range of Plasma IL6 and IL10 Levels.

IL-6 pg/ml
IL-10 pg/ml
Log IL-6 pg/ml
Log IL-10 pg/ml

Median (n=78)
167.9
20.8
5.1
3.0

Inter-quartile
Range
48.4 - 345.5
3.2 - 134.4
3.9 - 5.8
1.2 - 4.9
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Minimum
3.2
3.2
1.2
1.2

Maximum
3862.4
2066.5
8.3
7.6

Table 4-12. Median and Inter-quartile Range of Pro- and Anti-Inflammatory Cytokine
Levels by Genotypes.
IL-6 Levels pg/ml
IL-10 Levels pg/ml
Variables
(n = 78)
(n = 78)
Genotype: IL-6 SNP
CC
260.2 (90.4 - 406.8)
8.8 (3.2 - 36.3)
CG
176.7 (67.4 - 404.5)
68.7 (4.1 - 369.8)
GG
119.0 (28.0 - 293.1)
16.4 (3.2 - 132.8)
C Allele
195.3 (67.9 - 406.8)
36.2 (3.2 - 150.7)

10.2 (6.1 - 81.3)
3.1 (1.3 - 12.3)
4.9 (1.5 - 17.9)
5.7 (1.4 – 19.8)

Genotype: IL-10 SNP
AA
86.3 (24.5 - 257.8)
GA
163.4 (43.5 - 293.1)
GG
242.3 (98.1 - 633.7)
A Allele
157.1 (29.9 - 284.6)

2.2 (1.5 - 4.9)
9.2 ( 1.4 - 27.1)
6.1 (1.8 - 15.8)
4.7 (1.4 – 20.9)

58.3 (18.9 - 139.7)
3.2 (3.2 - 60.7)
43.5 (11.2 - 243.1)
10.5 (3.2 - 106.7)
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Figure 4-3. Box Plot of Plasma IL-6 levels by IL-6 Genotypes Pre and Post Log
Transformation.
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Figure 4-4. Box Plot of Plasma IL-10 levels by IL-10 Genotypes Pre and Post Log
Transformation.
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Figure 4-5. Box Plot of Plasma IL-6:IL10 ratios by IL-16 Genotypes Pre and Post Log
Transformation.
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Figure 4-6. Box Plot of Plasma IL-6:IL10 ratios by IL-10 Genotypes Pre and Post Log
Transformation.
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ratios among those who did and did not develop subsequent HAI (1.8 ± 1.5 vs. 1.6 ± 1.8,
p = 0.55). Cytokine levels were right skewed; thus, non-parametric tests were performed
to provide a comparison of median values among participants who did and did not
develop HAI. Median cytokine measurements are shown in Table 4-13. There were no
significant differences in baseline pro-inflammatory cytokines, anti-inflammatory
cytokines, or their ratios among participants who did and did not develop at least one
HAI during their ICU stay.
Aim 2
The goal of aim two was to investigate the variance in cytokine genes to
determine if they influence levels of protein expression or development of HAI.
The variance in cytokine genes were determined by SNP analysis. The
distribution of subjects per genotype is shown in Table 4-14. An ANOVA was performed
to examine the difference in cytokine means for each genotype. Table 4-15 and Figure
4-7 summarize the cytokine levels for each SNP. There were no significant differences in
plasma IL-6 levels based on SNP rs1800795. Both homozygous AA and GG genotypes
for IL-10 SNP rs1800896 were significantly higher (0.02) that the heterozygous GA.
Table 4-14 summarizes development of HAI by genotype and haplotype. There
were no statistically significant differences among genotypes or haplotypes for
development of HAI. There were no CC_AA, CC_GA, or GG_AA haplotypes among the
17 participants who developed HAI. The most common haplotype, was the heterozygous
CG_GA. This haplotype is also where the highest percentage of HAIs occurred but this
was not significant.
Aim 3
The goal of aim three was to investigate the effects of protein expression levels,
genetic variation, and environment on development of HAI. A series of Cox regression
analyses were performed among those who did and did not develop HAIs during ICU
stay (or up to 28 days in those with a prolonged ICU stay) controlling for a number of
potentially confounding variables. Table 4-16 provides a summary of variables testing
for inclusion into the multivariate model. Only variables with a p-value of less than 0.25
were included in the multivariate regression model (Table 4-17). There were only four
females in the study and it was not appropriate to include gender in the model (HR =
1313884).
Aim three included a series of questions pertaining to risk of developing HAIs. In
general, a hazard ratio greater than 1 indicates a higher risk of developing an event, in
this case health care associated infections, and a hazard ratio less than 1 indicates a lower
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Table 4-13. Comparison of Cytokine Levels among Subjects Developing HAI.
Variables
IL-6 pg/ml
IL-10 pg/ml
IL-6:IL-10 ratio

No HAI
(n = 61)
157.1 (251.8)
18.9 (129.6)
4.7 (16.4)

Developed HAI
(n = 17)
229.7 (571.4)
34.8 (144.6)
6.2 (11.6)

Note: Median and interquartile range shown.
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P
Value
0.21
0.55
0.78

Table 4-14. SNP Genotypes and Haplotypes for All Subjects by HAI Development and Pro- and Anti-inflammatory Cytokine
Quartiles.
Pro-inflammatory Cytokine: IL-6
1st-3rd
4th
P
Quartiles
Quartile
Value
59
19
.
.
0.67
5 (8.5)
2 (10.5)
.
20 (33.9)
8 (42.1)
.
34 (57.6)
9 (47.4)
.

Anti-inflammatory Cytokine: IL-10
1st-3rd
4th
P
Quartiles
Quartile
Value
59
19
.
.
0.56
6 (10.1)
1 (5.3)
.
19 (32.2)
9 (47.3)
.
34 (57.6)
9 (47.4)
.

Variables
N
IL-6
CC
CG
GG

All
Subjects
78
.
7 (9.0)
28 (35.9)
43 (55.1)

No HAI
61
.
6 (9.8)
20 (32.8)
35 (57.4)

HAI
17
.
1 (5.9)
8 (47.1)
8 (47.1)

P Value

IL-10
AA
GA
GG

.
17 (21.8)
38 (48.8)
23 (29.5)

.
16 (26.2)
29 (47.5)
16 (26.2)

.
1 (5.9)
9 (52.9)
7 (41.8)

0.15
.
.
.

.
15 (25.4)
29 (49.2)
15 (25.4)

.
2 (10.5)
9 (47.4)
8 (42.1)

0.26
.
.
.

.
12 (20.3)
32 (54.3)
15 (25.4)

.
5 (26.3)
6 (31.6)
8 (42.1)

0.57
.
.
.

Haplotype
(IL-6_IL10)
CC_AA
CC_GA
CC_GG
CG_AA
CG_GA
CG_GG
GG_AA
GG_GA
GG_GG

.
1 (1.3)
4 (5.3)
2 (2.3)
3 (3.9)
18 (23.1)
7 (9.0)
13 (16.7)
16 (20.5)
14 (18.0)

.
1 (1.6)
4 (6.6)
1 (1.6)
3 (4.9)
13 (21.3)
4 (6.6)
12 (19.7)
12 (19.7)
11 (18.0)

.
0 (0)
0 (0)
1 (5.6)
0 (0)
5 (29.4)
3 (17.7)
1 (5.9)
4 (25.5)
3 (17.7)

0.55
.
.
.
.
.
.
.
.
.

.
1 (1.7)
2 (3.4)
2 (3.4)
2 (3.4)
14 (23.7)
4 (6.8)
12 (20.3)
13 (22.0)
9 (15.3)

.
0 (0)
2 (10.5)
0 (0)
1 (5.3)
4 (21.1)
3 (15.8)
1 (5.3)
3 (15.8)
5 (26.3)

0.47
.
.
.
.
.
.
.
.
.

.
0 (0)
4 (6.8)
2 (3.4)
2 (3.4)
13 (22.0)
4 (6.8)
10 (17.0)
15 (25.4)
9 (15.3)

.
1 (5.3)
0 (0)
0 (0)
1 (5.3)
5 (26.3)
3 (15.8)
3 (15.8)
1 (5.3)
5 (26.3)

0.21
.
.
.
.
.
.
.
.
.

IL6 C Allele
IL10 A Allele

35 (44.9)
55 (70.5)

26 (42.6)
45 (73.8)

9 (52.9)
10 (58.8)

0.45
0.23

25 (42.4)
44 (74.6)

10 (52.6)
11 (57.9)

0.43
0.17

25 (42.4)
44 (74.6)

10 (52.6)
11 (57.9)

0.43
0.17

0.59
.
.
.
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Table 4-15. Cytokine levels by Genotype.
Genotype:
IL-6 SNP
CC
CG
GG

Log
IL-6
5.3
5.1
4.6

Standard
Deviation
0.6
0.3
0.3
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Genotype:
IL-10 SNP
AA
GA
GG

Log
IL-10
3.9
2.6
3.8

Standard
Deviation
0.5
0.3
0.4

Log IL-6
7
6
5
4
3
2
1
0

5.3

5.1

4.6

CC

CG

GG

Log IL-10
5

p = 0.02

4
3
2
1
0

3.9

2.6

3.8

AA

GA

GG

Figure 4-7. Log Plasma Cytokine Levels by Genotype.
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Table 4-16. Univariate Cox Regression Hazard Ratios for Development of HAI.
Variables
Age
Race
Body Mass Index (BMI)
Obesity (BMI > 30)
Diabetes
APACHE II
Baseline CRP
Baseline Plasma IL-10
Baseline Plasma IL-6
IL-6:IL-10 Ratio
IL-6 Genotype: CG
IL-6 Genotype: CC
IL-10 Genotype: GA
IL-10 Genotype: AA
Corticosteroids
Received Insulin during ICU Stay
Any Blood Products during ICU Stay
Received Antibiotics Prior to ICU
Appropriate Antibiotics in First 24 H
Invasive Device Score at HAI
Patient: Nurse Ratio > 2 to 1

Parameter
Estimate
0.070
1.150
-0.024
-0.199
-0.638
0.067
0.002
0.000
0.000
-0.009
1.435
1.563
1.391
1.348
0.283
-1.184
-0.123
-0.823
0.468
-0.037
0.494

Standard
Error
0.027
0.786
0.035
0.599
0.595
0.054
0.002
0.000
0.000
0.018
0.665
1.203
0.817
0.892
0.900
0.805
0.622
0.696
1.053
0.016
0.616

Chi-Square
6.481
2.137
0.480
0.110
1.152
1.497
1.695
0.340
0.285
0.237
4.656
1.688
2.895
2.284
0.099
2.163
0.039
1.396
0.197
5.546
0.644

Note: IL-6 and IL-10 genotype comparisons are made to GG genotype.
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P
Value
0.011
0.154
0.488
0.740
0.283
0.221
0.193
0.560
0.593
0.626
0.031
0.194
0.089
0.131
0.753
0.141
0.844
0.237
0.657
0.019
0.422

Hazard
Ratio
1.072
3.157
0.976
0.820
0.528
1.069
1.002
1.000
1.000
0.991
4.200
4.775
4.018
3.849
1.327
0.306
0.885
0.439
1.597
0.963
1.639

Table 4-17. Final Multivariate Cox Regression Model.
Variables
APACHE II
Invasive Device Score at HAI
Received Antibiotics Prior to ICU
IL-6 Genotype CC
IL-6 Genotype CG

ChiSquare
5.115
11.370
4.965
4.858
7.456

P Value
0.0237
0.0007
0.0259
0.0275
0.0063

Note: IL-6 Genotypes are compared to GG genotype.
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Hazard
Confidence
Ratio
Interval
1.241
1.029 - 1.495
0.908
0.086 - 0.961
0.106
0.015 - 0.763
28.097 1.447 - 545.653
14.959 2.146 – 104.295

risk of developing an event. Each question was answered based on univariate cox
regression modeling:
• The hazard ratio to predict development of HAIs for APACHE II is 1.069. For
each 10 point increase in APACHE II score the risk ratio or hazard ratio is e0.06656
x 10
= 1.956. For a 10 point increased in APACHE II score, there is a 95.6 percent
increase in the risk of developing a HAI.
• The hazard ratio to predict development of HAI for each additional invasive
devise is e-0.03742 = 0.963. For an additional invasive devise score there was a
3.7% lower risk of developing a HAI. The cumulative invasive devise score at the
time of HAI had been compared to the invasive devise score at ICU discharge
among participants who did not develop a HAI.
• The hazard ratio to predict development of HAIs given IL-6 -174G genotype CG
compared to GG is e1.43513 = 4.200, and for IL6 genotype CC compared to GG the
hazard ratio is e1.56334 = 4.775. Presence of the GG genotype has a four-fold
increase in risk for development of HAI.
• The hazard ratio to predict development of HAIs given IL-10 -1082G
genotypeIL-10 GA compared to GG is e1.39081 = 4.018, AA compared to GG is
e1.34786 = 3.849. Presence of the GG genotype has a four-fold increase in risk for
development of HAI
The hazard ratio to predict development of HAIs for each 10 point increase in
pro-inflammatory cytokine based on plasma IL-6 is e0.0001308 x 10 = 1.001. For a 10
point increase in IL-6 there is a 0.1% increase in developing a HAI.
• The hazard ratio to predict development of HAIs for each 10 point increase in
anti-inflammatory cytokine based on plasma IL-10 is e0.0002799x10 = 1.002. For a 10
point increase in IL-10 there is a 0.3% increase in developing a HAI.
• The hazard ratio to predict development of HAIs for each 10 point increase in
ratio of pro- to anti-inflammatory cytokine is e-0.00890x10 = 0.915. For a 10 point
increase in IL-6:IL10 ratio there is a 8.5% lower risk of developing a HAI.
The multivariate model included several predictors associated with HAI
development. All variable tested in univariate cox regression with a p <0.25 were
included in the final model. These variables included: age, race, APACHE II score,
invasive device score at first HAI, received insulin during ICU stay, baseline C-reactive
protein, received antibiotics prior to ICU, IL-6 genotype, and IL-10 genotype. Only
variables with of probability of < 0.05 were included in the final model. As some IL-6
genotypes were not significant, a dichotomous variable for genotype was created to
compared the CG and CC to the GG alleles. The final regression model is shown in
Table 4-17.
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CHAPTER 5. DISCUSSION
The purpose of this study was to determine the impact of baseline systemic
inflammation, genetic variability, and environment on the development of HAI among
patients with sepsis during their ICU stay. The sample consisted of 78 subjects, with 17
developing at least one HAI during or attributed to their ICU stay. Major findings in
general and by aim will be described as well as strengths, limitations, and implications
for these findings.
Major Findings
Baseline Infections
The most common infection responsible for sepsis at ICU admission in this study
was pneumonia, followed by UTI, skin and soft tissue infection, and gastrointestinal or
intrabdominal infection. The pattern of infection (site and organism) differs across ICU
populations as described in the discussion. This study focuses on medical ICU patients.
Our finding of pneumonia as the primary cause of sepsis causing ICU admission is in
agreement with some studies43,92 but urinary tract infections may precede pneumonia as
the primary cause.42
We found a significantly higher percentage of patients with high IL-6 levels
versus lower levels who developed arrhythmias during their ICU stay (52.6% vs. 18.6%,
p = 0.007). The median IL-6 difference was 303.3 vs. 98.1 (p = 0.0008) for those who
developed arrhythmias versus those who did not. This is consistent with emerging
literature. Aviles, et al. have shown that atrial fibrillation is associated with elevated
CPR levels, 117 and Boos provides a summary of four studies that found associations of
elevated CRP and IL-6 levels with atrial fibrillation and one study that did not.118
This population was composed primarily of males (97.9%), thus limiting
conclusion about females. It is well documented that males have a higher rate of
infections;119 however; this study included only 4 women. One female (25%) and 16
males (21.6%) developed HAI. This sample does not include enough females for a valid
comparison. There were no differences in the rate of HAI developed between white and
black patients in this study; however, we did find a difference in genotype among white
and black patients with sepsis who did and did not develop HAI. The literature reports a
higher incidence of infections in blacks as compared with whites.120
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First Health Care Associate Infection
The percentage of HAI caused by Candida (64%) was a surprising finding in this
study. Typically, the expected leading organisms associated with HAI are gram positive
(such as Coagulate-negative Staphylococcus, Staphylococcus aureus, and Enterococcus
spp.).43 This is a shift away from gram negative organisms in the past, and now Candida
species have emerged as the fourth most common cause of health care associated blood
stream infections.121,122 There were three species of Candida identified (Candida
albicans, Candida glabrata, Candida tropicalis) in addition to unidentified Candida
species. Colonization of the urinary tract with Candida is becoming more common and
the line between colonization and urinary tract infection is not easily distinguished.123
Among this sample, there were only two urinary tract infections (Candida species not
identified). There were two Candida albicans pneumonias, and all of the remaining
Candida infections were bloodstream infections (3 Candida albicans, 2 Candida
glabrata, 2 Candida tropicalis). The incidence of fungemia in the ICU had been
increasing and there have also been changes in the species pattern of Candida. Candida
albicans was the primary species in the 1980s, but now almost half of Candida infections
are non-albicans.124 The mortality associated with Candida glabrata is higher than
Candida albicans, 121,124 and Candida glabrata has been reported as the second most
frequent cause of Candidemia in US hospitals.121 Two primary risk factors associated
with Candida infections are colonization of the skin and mucous membranes and the
presence of invasive devices.122 Candida colonization is not always treated and the
urinary tract and upper airway may be colonized with Candida. Three patients with
Candida infections in this study were not treated. One patient had Candiduria which was
not treated and developed Candidemia three days later; however, the blood culture results
were not complete until after the patient had expired. Another patient with Candidemia
was not treated because care had been withdrawn before results were received, and
another patient with Candidemia expired before results were received.
Among all subjects developing infections, less than half (47%) developed fever or
hypothermia, in contrast to 74.4% experiencing fever or hypothermia at initial
presentation. Fever in the ICU is one of the triggers that lead to a careful clinical
assessment for its cause and possible laboratory assessments.54 Patients receiving
corticosteroids have a blunted febrile response due to down-regulation of inflammatory
mediators (IL-1β, TNF-α, IL-6) that cause fever. The threshold for laboratory assessment
(blood culture, BAL, and others cultures) is lower in patients receiving corticosteroids,125
which may explain why half of the infections were detected in the absence of fever.
Meduri et al. identified 60% of infections occurring after ICU day seven in patients
receiving corticosteroids in the absence of fever.126 The presentation of HAI required
less fluid resuscitation and fewer vasopressors (17% vs. 32%), than their initial ICU
presentation with sepsis.
A significantly higher number of patients who received corticosteroids developed
HAI compared to those who did not (82.4% vs. 42.6%, p = 0.005); however, when
controlling for other factors (shown in AIM3) this was not significant. Overall, patients
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who developed HAI had more invasive devices, more days of mechanical ventilation
(11.1 vs. 5.9, p = 0.03) and more days of ICU stay (15.3 vs. 6.4, p < 0.0001) when
compared to those who did not develop HAI. This is in agreement with literature which
consistently shows high correlation of these variables with development of HAI.42
Aim 1
The primary goal of aim one was to investigate whether baseline protein
expression levels of pro-inflammatory cytokines, anti-inflammatory cytokines, or their
ratios influence the development of subsequent HAI in patients with sepsis.
There were no significant differences in levels of pro-inflammatory cytokine,
anti-inflammatory cytokine, or their ratio among subjects who did and did not develop at
least one HAI during their ICU stay. Specifically, an exaggerated pro-inflammatory
response was present in 6 (31.6%) compared to 11 (18.6%) participants without an
exaggerated pro-inflammatory response who developed subsequent HAI. This difference
was not significant (p = 0.55). Likewise, an exaggerated anti-inflammatory response was
present in 5 (26.3%) compared to 12 (20.3) participants without an exaggerated antiinflammatory response who developed subsequent HAI. This difference was also not
significant (p = 0.43). There was also no significant difference in the log of
proinflammatory to anti-inflammatory ratios among those who did and did not develop
subsequent HAI.
One study investigated a similar relationship. Ramirez et al. performed a
prospective observational study to examine the relationship between systemic
inflammatory response and development of ventilator-associated pneumonia (VAP). 127
They included patients on mechanical ventilation who were expected to remain on
mechanical ventilation for more than 48 hours. They excluded patients who developed
other HAIs. They measured several cytokine (IL-6, Il-10, and others) at baseline and then
every 96 hours. Their sample included 44 patients, among which 9 developed VAP.
Findings included higher baseline IL-6 pg/ml among patients who subsequently
developed VAP. Higher median IL-6 pg/ml were reported for confirmed VAP cases (235
(188-620)) as compared to non-suspected (92 (43 - 167)), suspected (120 (112 - 161))
VAP cases (p = 0.02). They found no significant difference in median IL-10 pg/ml for
non-suspected (0 (0 - 4)), suspected (0 (0 - 4)), and confirmed (6 (3 - 12)) cases of VAP
(p = 0.16). They reported IL-10 detection limits of 1pg/ml.
The findings of Ramirez provide limited evidence that a clinical relationship
between exaggerated pro-inflammatory response and development of infections exists.127
In our study, we were unable to identify a difference. Our findings may be limited by the
timing of cytokine measurement and other factors. Baseline cytokine measurements were
collected at enrollment within 72 hours of developing sepsis. IL-6 levels usually peak
after IL-1β and TNF-α, around eight hours following an insult. The variation in timing
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for each subject (0 – 72 hours) and use of corticosteroids ( < 1 mg/kg) may have limited
these findings.
Aim 2
The goal of aim two was to investigate the variance in cytokine genes to
determine if they influence levels of protein expression or development of HAI.
Genotye and Cytokine Level
We examined cytokine levels by genotype and compared subjects grouped by
degree of inflammatory response. In Chi-square analysis comparing subjects with an
exaggerated inflammatory response to those without an exaggerated response, we found
no difference for rs1800795 or rs1800896. There were no significant differences in
median or log IL-6 level based on genotype rs1800795. We did find a significant
difference in IL-10 level based on genotype rs1800896. Participants who were
homozygous AA or GG had significantly higher log IL-10 levels than heterozygous GA
genotypes (0.02).
While promoter polymorphism may increase or decrease transcription levels,
there are also epigenetic and other factors that influence gene regulation. Taudorf et al.
studied the cytokine response to an endotoxin challenge in 200 young healthy men. They
found up to a 6 fold increase in cytokine levels following endotoxin injection but they did
not find significant differences in cytokine levels among many commonly studies
cytokine SNPs, including rs1800896 and rs1800795.100 Among all comparisons
involving genotype and cytokine level, we only found one difference. Other studies have
shown varied results.
Our findings, or lack of findings, may be limited by several factors. First, as noted
in aim one, timing of cytokine measurement may be a factor. An underlying assumption
of this research was that cytokine levels would be persistently elevated. This has been
well documented in the literature, particularly for non-survivors.87-89 This assumption
could not be evaluated in this study because plasma samples were only collected at
baseline and not over time. Second, variability in cytokine measures may be a factor.
This variability ranges from technician technique to the method selected for cytokine
measurement to the various proprietary antibodies used by different biotech companies
for each cytokine. Lastly, the findings of Taudorf suggest that either there may be no
difference or, more likely, there are several other factors that may be involved such that
these differences are not expressed in a healthier or less acutely ill population.
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Genotype and Development of HAI
There were no statistically significant differences among genotypes or haplotypes
for development of HAI. There were no CC_AA, CC_GA, or GG_AA haplotypes among
the 17 participants who developed HAI. The CC_GG haplotype was not observed in
another study.128 The most common haplotype was the heterozygous CG_GA. Baier, et
al., in a retrospective review of 293 low birth weight infants, investigated the IL-6
rs1800795 and IL-10 rs1800896 SNPs and sepsis outcomes. In their study, the rs1800795
C Allele was associated with late blood stream infections in African American but not
Caucasian infants. The incidence of blood stream infections was 69% in African
American infants with the C Allele compared to 46% in African American infants with
the GG genotype (p = 0.02). Racial differences have not been investigated in this
dissertation study and will be explored in future analyses. Baier et al. also found an
increased association of the rs1800896 A Allele with increased incidence of late blood
stream infections.128 The rs1800795 CC genotype has been associated with fungal blood
stream infections in Caucasians. This study population includes a large number of fungal
blood stream infections. Among the 7 participants with the rs1800795 CC genotype only
one developed a HAI, which was fungemia caused by Candida albicans.
Aim 3
The goal of aim three was to investigate the effects of protein expression levels,
genetic variation, and environment on development of HAI. A series of Cox regression
analyses were performed among those who did and did not develop HAIs during ICU
stay. Although the univariate models provided important risk ratios, the multivariate
model provides the variables most predictive for the risk ratio and can be used to predict
the risk of HAI development. We found no difference in protein expression levels, one
genetic variation, and two environmental factors that strongly predict risk of HAI
development. The final model included APACHE II, invasive devise score, and
antibiotics prior to ICU, and IL6 rs1800795.
Severity of illness contributes to risk of HAI development. Based on the
multivariate model, every one point increase in APACHE II score there is a 3.4%
increase in the risk of developing HAI. APACHE II scores range from 0 to 71 with a
higher scores associated with a worse outcome.38 The APACHE II has been correlated
with baseline inflammatory response but not HAI development.12 Patients with a higher
severity of illness require a higher level of care. These patients are potentially exposed to
a higher risk due to the presence of more invasive devices and also have a higher
exposure to multiple hospital personnel and equipment needed to provide their care. For
each additional invasive device there was a 9.1% reduced risk in the development of
HAI. This does not make intuitive sense. It is likely that the format of the invasive device
score used in the model is problematic and additional models will be explored using only
the number of invasive devices present at the time of HAI, rather than the cumulative
score. Table 4-6 provides the cumulative invasive device score at the time of HAI (52.8
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± 26.7) and Table 4-8 provides the cumulative invasive device score at ICU discharge
(23.9 ± 23.0) for those who did not develop HAI. More investigation is needed to fully
assess these findings.
We found that early antibiotic use prior to ICU stay reduces risk of HAI in
patients with sepsis. The importance of early antibiotic use has been incorporated into
several guidelines. The surviving sepsis campaign recommends antibiotics within the first
hour for septic shock.26 The IDSA recommends antibiotic administration in the ER prior
to ICU admission for patients with CAP.55 In this study, we examined whether patients
received antibiotics before transfer to the ICU. The early administration of antibiotics
reduces morality associated with sepsis and may, according to Zubert, be a “surrogate
marker for quality of care in the broader sense”. 129 While early antibiotic use is
important, appropriately deescalating therapy based on culture sensitivities is also
important.130
The presence of IL6 rs1800795 CC compared to GG and GC compared to GG had
a higher risk in the univariate mode, and the risk increased in the multivariate model
when controlling for other variables. The final model included only variables that were
significant (p < 0.05). The higher risk associated with rs1800795 genotypes CG and CC
is consistent with higher risk associated with the C allele noted in the literature. The
rs1800795 C Allele has also been found to be associated with late blood stream infections
in African American infants,128 and has been shown to be more prevalent in coronary
artery patients developing myocardial infarction compared to coronary artery patients
with stable and unstable angina.131 More analysis is needed to fully explore the
relationships of these variables.
Strengths
Study strengths are summarized below:
1.

2.
3.

This study occurred in a teaching hospital where the attending physicians and
medical team rotate monthly; however, the MICU team include a PharmD who is
present for daily rounds with the team in the morning and afternoon on Monday
through Friday. This provides consistency in patient management in regards to the
appropriate use, selection, and dosing of antibiotics in the ICU. This PharmD
reviewed cultures and antibiotics with me to determine appropriate antibiotics
based on current guidelines.
This study occurred in one facility, limiting the biases that could occur at multiple
sites by multiple data collectors.
The inclusion of biomarkers and use in a multivariate model strengthens
conclusions about risk factors associated with development of HAI.
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Limitations
Study limitations are summarized below:
1.

2.
3.
4.
5.

6.
7.
8.
9.

A potential limitation of this study was the heterogeneous sample. Some patients
were not as sick as others and were discharged from the ICU prior to three days.
Since development of HAI has been strongly associated with length of stay, this is
a limitation that was accounted for by using Cox regression modeling.
Limiting this study to a single site with primarily older male veterans limits
generalizability of findings.
It was a major assumption that baseline systemic inflammation would be
prolonged. Measuring only baseline cytokine levels is a limitation.
The usage of corticosteroid therapy may impact the degree and duration of
systemic inflammation; thus, potentially limiting the possible impact of systemic
inflammation on the development of HAI in participants receiving corticosteroids.
The use of corticosteroids may limit fever among participants experiencing HAI,
and may result in failure to detect HAI when they occur. It is recommended
clinical practice in our ICU to use sepsis surveillance, and thus a high degree of
suspicion when steroids are used.
There may be other predisposing factors for development of HAI that were not
measured.
The investigator is a novice bench researcher, and although efforts were made to
accurately follow protocols, it is possible that errors could have influenced results.
Endpoint genotyping of rs1800896 required manual calls in seven samples.
Interleukin 6 was selected as a proinflammatory cytokine; however, it does have
some anti-inflammatory properties.
Implications

This study provides important insights into risk factors that contribute to the
development of HAI in patients presenting to the ICU with sepsis. These findings may
impact nursing and other critical care clinician practice first by helping to identify
patients at risk, then implementing stricter targeted infection control practices in efforts to
prevent development of HAIs (in addition to current standard and recommended
practices). JACHO patient safety goals include prevention of HAI.
Since the completion of this study, new processes are in place in the facility
where this study occurred. These including daily surveillance of central line sites and
implementation of a UTI bundle to reduce UTI. The findings of this study reveal a need
to further investigate the cause of Candida in this population and to follow-up on the
incidence of Candida in this unit. The use of antibiotic timing and duration should be
reviewed. A high percentage (9 of 11, 81.8%) of the Candida infections occurred during
corticosteroids use, indicating a need to assure appropriate sepsis surveillance is followed
in patients receiving corticosteroids. Specific nursing measures would include a review of
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standard IV care practices such as tubing changes, site rotation for peripheral lines,
duration of central lines, routine site evaluation and care, hub care, cleaning of IV
equipment, cleaning of transducer holders, and no re-use of disposable pressure bags.
This may include changing the catheter hub after blood draws when flushing cannot
completely clear the hub as well as protocol driven hub care.
Cleaning the environment closest to the patient needs to be considered. The side
rails, call light, bed controls, and equipment in use in the room are typically only cleaned
when they become soiled. These items could be wiped down with sanitary wipes daily
when other areas of the room are cleaned. Cleaning of other environmental areas would
include routine cleaning of medication carts, including the front of medication drawers,
keyboard, scanner, and the work surface. Routine cleaning of the sink handles and light
switches should also be evaluated.
Conclusions
This study provides evidence of a genetic risk for development of HAI. Despite
best evidenced based practices some patients will develop HAI. Strict aseptic technique is
essential to preventing infection. In addition to eliminating invasive devices as quickly as
possible, patients with a high severity of illness may need to be isolated to lower their
risk. Early administration of antibiotics not only provides prompt treatment for the initial
infection but also lowers risk for subsequent infections.
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